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ABSTRACT
The discovery and implementation of immunomodulatory drugs (IMiD®s) has
revolutionized the treatment of many hematological malignancies due to the plethora of
IMiD®-induced clinical responses that include anti-angiogenesis, anti-inflammation, and
anti-tumor effects, as well as enhanced erythropoiesis, immune modulation and improved
metabolism. More ground-breaking was the identification of cereblon as the target of
IMiD®s. Upon binding to thalidomide and other immunomodulatory drugs, the E3 ligase
substrate receptor cereblon (CRBN) promotes proteosomal destruction of neo-substrates
by engaging the DDB1-CUL4A-Roc1-RBX1 E3-ubiquitin ligase in human cells but not in
mouse cells suggesting that sequence variations in CRBN may cause its inactivation.
Therapeutically, CRBN engagers have the potential for broad applications in cancer and
immune therapy by specifically reducing protein expression through targeted ubiquitinmediated degradation. To examine the effects of defined sequence changes on CRBN’s
activity, we performed a comprehensive study using complementary theoretical,
biophysical, and biological assays aimed at understanding CRBN’s non-primate
sequence variations. With a series of recombinant thalidomide-binding domain (TBD)
proteins, we show that CRBN sequence variants of different species retain their drug
binding properties to both classical immunomodulatory drugs and to dBET1, a chemical
compound and targeting ligand (i.e. a PROTAC) designed to degrade bromodomaincontaining 4 (BRD4) via a CRBN-dependent mechanism. We further show that dBET1
stimulates CRBN’s E3 ubiquitin-conjugating function and degrades BRD4 in both mouse
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and human cells. This insight provides evidence that mouse CRBN is functional and
provides a new avenue of exploring CRBN’s endogenous substrate recruiting function in
hematopoietic cells.
Hematopoietic stem cell (HSC) ontogeny is governed by extrinsic and intrinsic
programs to control proliferation, localization, differentiation and self-renewal. The E3
ubiquitin ligase substrate receptor CRBN is expressed in hematopoietic lineages,
including long-term HSCs (CD48-CD150+Lineage-Sca-1+c-Kit+ (LSK)), but plays an
undefined role in hematopoiesis. As CRBN is the only confirmed target of IMiD®s and
since IMiD®s have substantial clinical activity in a number of hematological malignancies,
CRBN’s involvement in hematopoiesis was investigated. In these diseases, the IMiD®CRBN interaction is associated with tumor cell death and other cellular responses through
at least two major proposed mechanisms including, 1) drug-induced activation of
neomorphic protein degradation, and 2) inhibition of endogenous substrate recruitment
leading to toxic protein accumulation[3]. To gain insights into the role of CRBN in
hematopoiesis, we assessed adult steady state and transplant-associated hematopoiesis
and evaluated HSC development during embryogenesis using germline Crbn-/- mice.
Compared to Crbn+/+ mice, CRBN deficiency was associated with a 2-3-fold reduction in
stem cells in adult bone marrow and a similar reduction in HSCs in the fetal liver at
embryonic stage 14.5 when the HSC pool is initiated from several anatomical sites
including the yolk sac, aorta gonad mesonephros and fetal liver. Postnatal bone marrow
HSCs are maintained throughout life by a process of self-renewal and differentiation.
Interestingly, mature lymphoid and myeloid progeny were moderately expanded in
peripheral blood of Crbn-/- mice under homeostatic conditions and following serial bone
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marrow transplantation suggesting that CRBN is critical for stem cell maintenance. RNAseq analyses and qRT-PCR validation of BM-derived Crbn-/- LSKs and HSCs showed a
marked suppression in a “stemness”-related gene signature consisting of Tie2, Hif1α, and
Notch1 suggesting that CRBN is required to maintain HSCs in the undifferentiated state.
Moreover, high amounts of proliferation within the LT-HSCs at steady-state, increased
mature cells at steady-state and following serial transplantation, and increased lethality
to repeated 5-fluorouracil (5-FU) challenge in Crbn-/- mice indicate that CRBN maintains
HSC quiescence. Collectively our data suggest CRBN functions to maintain HSC
quiescence required to maintain the undifferentiated properties of the HSC cells in the
adult bone marrow. HSCs reside in highly specialized bone marrow niches where multiple
cooperative networks of intrinsic and extrinsic factors are required for HSC homeostasis.
Transplantation of Crbn+/+ HSCs into Crbn-/- recipients failed to generate a defined
phenotype. However, HSC adhesion (Vcam1, Cxcr4)-associated genes were significantly
suppressed. Particularly, the G protein-coupled chemokine receptor CXCR4-CXCL12
interaction which controls fetal and mature BM colonization and regulates homeostatic
and regenerative HSC maintenance. These results indicate that CRBN is a functional
protein in rodents and demonstrates a novel role for CRBN in the control of hematopoiesis
with important implications in understanding how IMiD®s exert their therapeutic actions
in hematological cancers.
Our results demonstrate a novel role for CRBN in the control of hemopoiesis with
important implications in understanding how IMiD®s exert their therapeutic actions in
hematological cancers.
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CHAPTER ONE
INTRODUCTION
A note to the reader: Portions of this chapter have been previously published in
a review article in Integrated Cancer Science Therapy, Akuffo et al[4] and has been
reproduced here with permission from the publisher.

The history of immunomodulatory (IMiD®s) compounds
Thalidomide, first developed in Germany in 1956, is infamously known for
its teratogenic properties when used to treat hyperemesis gravidarum and for
sedation [5]. From the late 1950s until 1962, use of this drug rapidly expanded to
48 countries where it was responsible for birth defects ranging from congenital
heart disease, malformations in limb development and ocular abnormalities in
thousands of children. While initial preclinical data suggested that thalidomide had
an acceptable safety profile in rodents, testing in pregnant animals was not a
mandated practice at the time [6]. The tragedy of thalidomide rapidly led to
significant changes in the processes required for medical product development
throughout the world with enactment of an amendment to the United States
Federal Food, Drug and Cosmetic Act in 1962 requiring more rigorous preclinical
testing for new pharmaceuticals[7].
In the early 2000s, thalidomide was repurposed in the clinic as a potent antiangiogenic[8] and immunomodulatory compound for the treatment of multiple
myeloma (MM), myelodysplastic syndrome harboring a chromosomal deletion in
1

5q (del (5q) MDS) and other hematological malignancies [9-11](Figure 1). The drug
was approved for cancer treatment under an FDA directive requiring routine
pregnancy testing with distribution of written and verbal warnings to inform patients
of the detrimental impact of thalidomide on fetal development[12]. Many studies
have confirmed the relationship between thalidomide, and its related class of
compounds (also known as immunomodulatory drugs, IMiD®) and teratogenicity
in humans, zebrafish, chickens and in rodents when given during specific periods
of gestation [5, 13-15].

Figure 1. The history of IMiD®s. Timeline showing the discovery, development
and application of immunomodulatory compounds. pthalimide (PHTH, grey, an
inactive derivative), thalidomide (THAL, blue), lenalidomide (LEN, green),
pomalidomide (POM, orange) & avadomide (AVA/CC-122, cyan)
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Mechanism of IMiD®s in Hematological Malignancies
Despite its infamous history, over the past decade, the discovery,
development, and approval of IMiD®s (thalidomide (Thalomid®), lenalidomide
(Revlimid®), pomalidomide (Pomalyst®) and avadomide) in combination with
proteasome inhibitors (e.g., bortezomib (Velcade®) and carfilzomib (Kyprolis®)
and anti-inflammatory compounds (e.g., dexamethasone ) have revolutionized the
treatment of hematological malignancies. Many pharmacological studies have
demonstrated that IMiD®s act both to modulate immune function and to directly
kill tumor cells by inducing the expression of pro-apoptotic molecules and by
severing interactions between tumor cells and their microenvironment [8, 9, 16,
17]. In del5q MDS, lenalidomide was shown to induce cell death through synthetic
lethality caused by haplo-insufficient genes on chromosome 5[18].
Malignant hematological disorders give rise to cells that evade immune
surveillance, impair normal immune cell function and have enhanced metastatic
colonization potential. For example, in multiple myeloma (MM), aberrant plasma
cells (PC) secrete immunosuppressive factors such as interleukin 10 (IL-10), IL-6,
transforming growth factor beta (TGF-β) and vascular endothelial growth factor
(VEGF) that ultimately lead to weak antigen presentation, dysfunctional innate and
adaptive immunity and suboptimal tumor-specific immune response[19-23].
Furthermore, MM-bone marrow stromal cell (BMSC) and -extracellular matrix
(ECM) interactions promote tumor survival through:
1. Amplification of a myriad of adhesion molecules such as chemokine
receptor 4 (CXCR4), very late antigen 4 (VLA-4), leukocyte function3

associated antigen (LFA -1), and syndecan-1 (CD138) on tumor cells,
vascular cell adhesion molecule (VCAM-1) and intercellular adhesion
molecule (ICAM-1) on BMSC.
2. Activation of NF-κB, a transcription factor that promotes growth and
survival in both normal and malignant cells)[24] and secretion of TNFα,
a potent mediator of inflammation and osteoclastogenesis [25].
3. Stimulation of signaling pathways critical to tumor growth including
mitogen-activated protein kinase (MAPK), Janus kinase (JAK)/ signal
transducers and activators of transcription (STAT), IκB kinase (IKK)α/NF-κβ and phosphatidylinositol-3 kinase (PI-3K)/Akt pathways).
IMiD® treatment disrupts MM–BMSC-dependent survival advantages
through several mechanisms including blocking VEGF production (antiangiogenesis)[26, 27], limiting TNFα secretion (anti-inflammatory effects) [25],
modulation of IL-6 and other crucial cytokines and chemokines production and
downregulation of adhesion molecules[19-23].
Cereblon’s structural features
The mechanisms underlying the adverse effects and pleiotropic therapeutic
responses of IMiD®s remained unclear, due to a lack of known targets, until
Takumi Ito and colleagues revealed the molecular mechanism of these
compounds through elegant studies conducted in zebrafish and chickens [28]. In
the study, Ito and colleagues identified cereblon (CRBN) as the direct target of
immunomodulatory compounds and one of many DDB1 and CUL4-associated
4

factors (DCAFs) that directs protein turnover by ubiquitination and subsequent
proteasome recognition. Cereblon is 442 residues long with a disordered region in
the N-terminal, two LON domains, (N-terminal LON and C-terminal LON),
connected by DDB1-binding region and a thalidomide-binding motif (TBD) in the
C-terminal [29] (Figure 2A).

Figure 2. Structure of CRBN and IMiD®s. (A) Ribbon structure of CRBN showing
LON domains (LON-N orange, LON-C cyan), DDB1-bininding domain (grey),
disordered region (pink), zinc (red), lenalidomide (Len)(green) interacting in TBD. (B)
The region of the thalidomide-binding domain (TBD) indicated (red) interacts with the
glutarimide ring of the IMiD®s, whilst the second ring (phthalIMiD®e, isoindolinone
and quinazolinone) interacts with the CRBN TBD and its substrates (Ikaros, Aiolos,
CK1α, and unknown proteins), respectively.
5

Cereblon acts as a substrate recruiting module for the DDB1–CUL4A–
Roc1–RBX1 E3 ubiquitin ligase complex and the immunomodulatory compounds
thalidomide, lenalidomide, pomalidomide, and avadomide (Figure 2B) alter its
recruiting functions by attracting various “neo” protein substrates including Ikaros,
Aiolos, [14] and casein kinase 1α (CK1α) to [15, 30] the DDB1-CUL4A-Rbx1
complex (Figure 3). This drug class is characterized by a common structural
feature, the glutarimide ring (Figure 2B) which interacts directly in the hydrophobic
pocket of cereblon’s TBD. The remainder of the molecule, the solvent exposed
portion, is also quite similar among the four drugs, with only the presence or
absence of an amino group or a carbonyl group rounding out the structural
differences (Figure 2B). This portion of the compound is also responsible for “neo”
substrate recruitment and has been shown to reinforce interactions between
substrate and the TBD[31].

Figure 3. Schematic of CRBN’s degron properties
6

IMiD®-mediated effects in humans versus mouse
It is now well established that immunomodulatory drug-dependent
degradation of Ikaros and Aiolos encoded by IKZF1 and IKZF3 respectively,
potentiates human T cells [32-34] and is partially responsible for the cytotoxicity of
human MM cells [14]. CK1α degradation is selectively targeted by lenalidomide
which garners an apoptotic phenotype that is uniquely associated with clinical
responses in del(5q) MDS [15, 35] and MM [36]. A complete list of identified IMiD®dependent “neo” substrates can be found in Table 1 below.
Despite advances in our understanding of immunomodulatory drugs and
their molecular mechanism, the notion that mice and other rodents are “resistant”
to immunomodulatory compounds has been widely circulated due to the initial
reports concluding that pups born from thalidomide-treated pregnant dams had no
limb abnormalities[37]. This observation was also followed by several studies
showing species-dependent differences in thalidomide metabolism[38, 39]. Follow
up studies conducted with extremely higher concentrations of thalidomide [40] or
mutant mice that are deficient in antioxidant enzyme showed mice can be made
sensitive to thalidomide embryopathy under specific conditions[41].
Few medical disasters have reached the level of thalidomide-associated
teratogenicity and have had such prevailing consequences in its aftermath.
Moreover, as most preclinical compounds are tested in mice, it has become
imperative to thoroughly investigate the mechanism of action of preclinical
compounds to uncover any divergent clinical responses between humans and
mice to prevent teratogenic disasters.
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Table 1. “Neo” substrate recruitment by IMiD®s and their clinical use
Compound

CompoundSpecific
Target

Targetspecific
Effect

Clinical use

All IMiD®s

IKZF1&3

IRF4¯

T , B, & NK cell function,
Anti-myeloma
Anti-angiogenesis
Anti-inflammatory
¯Cell-adhesion-mediated drug
resistance[42]

Lenalidomide

Ck1𝛼

p53
¯Myc

Anti-MDS (non & del(5))[43]
Anti-Myeloma[36]

Avadomide
(CC-122)

Currently
unknown

IFN-β

Anti-DLBCL[44]
(In Clinical Trials)

Iberdomide
(CC-220)

Currently
unknown

Currently
unknown

Treats pomalidomide
resistant myeloma[45]

CC-885

GSPT1

None (Toxic to healthy cells)

Drugging the undruggable with PROTACs
Nearly two decades ago Sakamoto, Crews and Deshaies sought to
artificially

direct

intracellular

protein

degradation

by

synthesizing

a

heterobifunctional molecule, Protac-1, which tethers IκBα phosphopeptide that is
recognized by Skp1-Cullin-F box complex containing Hrt1 (SCF) complex
substrate receptor F-box protein β-TRCP[46] to ovaclin inhibitor, MetAP-2. Protac1 successfully bound MetAP-2 to SCFβ-TRCP and promoted MetAP-2
ubiquitination and degradation. Though a gamechanger in drug design, this
technology, dubbed proteolysis targeting chimera (PROTAC), did not gain
widespread traction due to poor cellular permeability and the lack of specificity of
the peptide moiety of the molecule. Several years later with the discovery of
compounds with improved affinity and specificity to various E3 ubiquitin ligase
8

substrate receptors and exceptional cell permeability, PROTAC has emerged as a
robust method to “drug the undruggable proteome[47]”.
Currently, four E3 ligases (MDM2, cIAP1, CRBN (cereblon) and von HippelLindau (VHL)) are being used as the basis for PROTAC compound design. See
Table 2 for summary of developed PROTACs and some advantages and
limitations of PROTACs. IMiD®-based PROTAC compounds dramatically
improved affinity and specificity of the high order three dimensional complexes that
is required for function including a stable E3 ubiquitin ligase interaction, substrate
receptor engagement, and protein target complex. These features along with
excellent medicinal properties, including exceptional cell permeability, has led to
clinical testing of IMiD®-based PROTACs.
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Table 2. PROTACs: the advantages and disadvantages of their use[48, 49]

Thalidomide–related/IMiD®-based compounds are key components of
PROTAC technology due their fidelity in hijacking the CRBN/DDB1/Cul4A/ Rbx1
E3 ubiquitin ligase complex [50]. Given that thalidomide and its derivatives
selectively bind CRBN, dBET1 was one of the first synthesized IMiD®-based
PROTAC to induce the degradation of BRD4, a BET-family protein[51] (Figure 4).
Using dBET1, a thalidomide-JQ1 PROTAC, Winter et al observed a >85%
decrease in BRD4 expression (at nanomolar concentrations), subsequent
decrease in oncoproteins c-Myc and PIM-1 that collectively led to superior
apoptosis induction both in vitro AML cell-based assays and in an in vivo murine
xenograft model of AML than JQ1 [51].
10

Figure 4. Proteolysis targeting chimera (PROTAC) modular structure and
mechanism of action. (A) Schematic of structure of BET bromodomain-targeting
PROTAC, dBET1[51]. (B) Chemical structure and modality of dBET1; thalidomide
(CRBN-specific compound) linked to JQ1 (BET family-specific compound) is able
to recruit BRD4 to cereblon E3 ubiquitin ligase complex. dBET1 is highly selective
cereblon-dependent BET protein degrader.
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Other IMiD®-based PROTACs have shown superior inhibition of protein
function and more potent anti-tumor effects than their parent compound[52, 53].
One in particular, PROTAC P13I, which adopts ibrutinib as a warhead and
pomalidomide to recruit CRBN, was synthesized to target BTK degradation and
was observed to target both wild-type and mutant forms of BTK [54, 55]. PROTAC
P13I elicited better therapeutic responses and limited drug-resistant mechanism
employed by human DLBCL cell line.
A study conducted by Zhu et al demonstrated that CRBN suppression
via CRBN shRNA lentiviral expression constructs is cytotoxic to human MM cell
lines[56]. These results reveal an IMiD®-independent role of cereblon in MM
survival which prompted the development of homo-PROTAC molecules designed
to self-degrade CRBN[57]. Chemical knockout down of CRBN had a modest effect
on the viability of MM cell line (↓ 20%) in comparison to parental compound
pomalidomide ( ↓ 90%).

Though chemical CRBN degradation did not have

superior anti-tumor effects as predicted, CRBN degraders will be useful tools for
unraveling endogenous substrates and physiological roles of CRBN and providing
additional insights into the molecular mechanism of IMiD®s.
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Cereblon’s endogenous role
Our understanding of IMiD®-dependent and independent roles of CRBN is
still poorly understood due to its innately promiscuous function. Currently, IMiD®independent functions have been shown to include the modulation of AMPK[58],
AGO2[59],

glutamine

synthase[60],

MEIS2[13],

CD147-MCT1

complex

formation[61]. Although the aforementioned targets have not been crystalized with
CRBN in X-ray crystallography, they all share the characteristic β-hairpin loop
structure and a key glycine residue known to directly engage the pthalimide moiety
of IMiD®s.
Metabolism diseases:
obesity, diabetes,
hypertension

AntiMM
Regulate
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Figure 5. Summary of IMiD®-dependent and independent functions of
CRBN. Adapted from Shi et al. [1]
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Collectively the IMiD®-independent and dependent targets of CRBN are
centered on processes such as cell metabolism, proliferation and embryonic
development and appear to be cell-type specific[1](See Figure 5 for summary).
Since IMiD®s have shown successful clinical responses in hematological
malignancies, investigation into CRBN’s endogenous function in hematopoietic
cell lineages could improve our understanding of the therapeutic vulnerability of
CRBN.

Introduction to Hematopoiesis
Hematopoiesis is the continuous production of mature blood cells from a
rare pool of self-renewing hematopoietic stem cells (HSC). HSCs sit at the top of
a complex hierarchical system and are faced with the decision to remain quiescent,
self-renew, differentiate, migrate/mobilize, or die [62]. Early studies by Weissman
and colleagues identified a combination of cell surface markers that robustly
classifies the pool of mouse (Lin-, CD34low/-Sca-1+, Thy-1.1+/low, c-Kit+, CD38+)
[63] and human (Lin-, c-Kit-/low, CD38low/-, Thy-1. 1+, CD59+, CD34+)[64, 65]
hematopoietic stem and progenitor cells (HSPCs) capable of restoring a functional
blood network when transplanted into lethally irradiated mice. Genetic and
proteomic profiling in recent years have further fractionated HPSCs based on their
cell surface markers and propensity to give rise to specific lineages in
transplantation and in vitro colony formation assays[66].
In the classical hierarchal classification (Figure 6A), HSCs can be divided
into two main subsets: long-term hematopoietic stem cells (LT-HSC) that are
14

capable of perpetual self-renewal, and short-term hematopoietic stem cells (STHSC) that self-renew for a defined interval[62]. ST-HSCs give rise to non–selfrenewing multipotent progenitors (MPP), which in turn give rise to two progeny that
are more restricted in their differentiating potential, the common myeloid progenitor
(CMP) (with myeloid, megakaryocyte and erythroid potential) and the common
lymphoid progenitor(CLP) (with only lymphoid potential). CMP further differentiate
into bipotent granulocyte-macrophage (GMP) and megakaryocyte-erythroid (MEP)
that eventually give rise to terminally differentiated neutrophils, basophils,
eosinophils,

macrophages,

monocyte-derived

dendritic

cells,

and

megakaryocytes, platelets and erythrocytes, respectively (Figure 6). CLP give rise
to T cells, B cells, natural killer (NK) cells and dendritic cells (DC) (Figure 6A).
Although this hierarchical system of differentiation was initially thought to be
a one-directional stepwise process, recent studies challenge this models and
suggest that stem cells are in a continuum of change[67-69]. Yamamoto et al and
Sanjuan-Pla et al through single-cell sequencing and transplantation, identified
myeloid-restricted progenitors with long-term repopulating activity and selfrenewing platelet-primed HSCs the preferentially differentiate into platelets but
have a long-term myeloid lineage bias, and can give rise to lymphoid-biased HSCs
[70, 71]. These studies, among others, suggests a continuous differentiation model
in which HSCs acquire lineage biases along multiple directions without passing
through discrete hierarchically organized progenitor populations[67, 69, 72]
(Figure 6B).
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Table 3. Characterization of hematopoietic lineages
Population

Surface
Markers

Self-renewal
high (H), moderate(M), low
(L) or no (N)?

Cell Cycle at steadystate

LT-HSC

Lin-, Sca-1+, c-Kit+,
CD34-, CD135-, CD48CD150+

H

G0: ~70%
G1: ~20%
S-G2/M: ≤10%

ST-HSC

Lin-, Sca-1+, c-Kit+,
CD34+, CD135-, CD48CD150-

MPP

Lin-, Sca-1+, c-Kit+,
CD34+,CD135+,CD48+,
CD150-

M

G0: ~ 60%
G1: ~20%
S-G2/M: ≤ 20%

M

G0: ~ 50%
G1: ~40%
S-G2/M: ≤ 20%
G0: ~ 10%
G1: ~ 60%
S-G2/M: ≤ 20%

LSK

Lin- , Sca-1+, c-Kit+

L

LK

Lin-, c-Kit+

N

Lin-

Gr1- CD3- CD4- CD8B220- CD11b- Ter119CD19- CD127-

N
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G0: ~ 10%
G1: ~ 60%
S-G2/M: ≤ 20%
G0: ~ 10%
G1: ~ 60%
S-G2/M: ≤ 20%

A

B
Mouse

Human

HSC

Self-renewal

Multipotent
progenitors

Differentiation

/ST-HSC

CLP
Oligopotent
progenitors

CMP
MEP

/LMPP

Mature
effector
cells

Lineage
restricted
progenitors

GMP

MkP

Platelets

EP

GP

MacP

Pro-DC

Pro-B

Erythrocyte
Macrophages
B-cells
Granulocytes
Dendritic cells

Pro-T

T-cells

Pro-NK

NK-cells

Figure 6. Classical versus revised mouse and human hematopoietic cell
hierarchy. (A) The hematopoietic system is orchestrated by self-renewing
hematopoietic stem cells (HSCs), which can be subdivided based on their temporal
ability to sustain the whole spectrum of mature blood cell lineages. HSCs with selfrenewal capabilities give rise to multiple types of multipotent progenitor cells (MPP),
oligopotent progenitors: common lymphoid progenitors (CLPs), common myeloid
progenitors (CMPs), granulocyte–macrophage progenitors (GMPs), and
megakaryocyte–erythrocyte progenitors (MEPs), lineage restricted progenitors
(megakaryocyte progenitor (MkP), erythrocyte progenitor(EP), granulocyte progenitor
(GP), macrophage progenitor (MacP), pro-dendritic cell (ProDC), pro-B cell (Pro-B),
pro-T cell (Pro-T), pro-natural killer cell (Pro-NK)) and finally mature blood cells of
different lineages that, with some exceptions (certain B cell and T cell subsets, and
tissue-resident macrophages), do not self-renew. (B) The revised hierarchy that
describes HSC irreversibly differentiating into multipotent progenitors with lineage
biased that give rise to a primary specific linage (thicker arrows) but infrequently give
rise to other lineages (thinner arrows).

Hematopoietic stem cell origin.
To understand the cell fate of HSCs and the factors leading to their
heterogenicity much research has focused on their developmental origins. The
early stages of mammalian hematopoiesis begin in the blood islands of the yolk
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sac, during embryonic development and has been classified into two stages:
primitive and definitive hematopoiesis[73-75]. Primitive (embryonic) hematopoiesis
begins approximately at embryonic stage 7.5 (E 7.5) in mouse and 2 weeks in
humans and is shortly followed by definitive (fetal) hematopoiesis which begins
between E10 to E11 in mice and as early as 8 weeks in the aorta–gonad–
mesonephros (AGM) region (Figure 7A). While primitive HSCs give rise to mainly
nucleated pro-erythrocytes, definitive HSCs are able to give rise to all the blood
lineages. HSCs undergo rapid activation and expansion in the AGM and thereafter
migrate to the fetal liver where they undergo further expansion. Subsequently
definitive HSCs localize to the bone marrow, thymus and spleen. After birth, the
bone marrow becomes the main site of blood cells production and hematopoietic
stem cells maintenance for the organism’s lifetime.
In adult BM at homeostatic conditions, HSCs primarily become quiescent
only dividing intermittently. Though broadly investigated, our understanding of the
factors that determine HSC cell fate is limited. Thus far, studies have demonstrated
that HSC pool itself is functionally and molecularly heterogeneous and that a
combination of cell autonomous drivers and extrinsic molecular cues from nonhematopoietic and HSC-derived niche cells control HSC heterogenicity.
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Figure 7. Hematopoietic niches during development. (A) Primitive (embryonic)
hematopoiesis occurs in the yolk sac while definitive hematopoiesis occurs in the
AGM region. At specified times HSCs migrate from AGM to the fetal liver and finally
to the bone marrow, spleen, and thymus. (B) Illustration of adult bone marrow
niche. Quiescent HSCs are located in the arteriole niches whereas activated HSCs
are sinusoidal niche. NG2+ pericytes, Leptin receptor expressing (LepR+)
perivascular cells, sinusoid, Mesenchymal stromal cells (MSC), CXCL12-abundant
reticular (CAR) cells, megakaryocytes, macrophages, and sympathetic neurons
are components of the HSC niche that work together to regulate HSC
maintenance. A combination of HSC receptors (TIE2, MPL, CXCR4,c-KIT) and
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niche adhesion molecules and secreted factors, CXCL12, ANG, TPO, TGFβ,
CXCL4, JAGGED, work collaboratively to regulate HSCs maintenance, retention,
dormancy and expansion.
Cellular components of the bone marrow niche
The microenvironment in which HSC reside, referred to as the HSC niche,
is an important determinant of the equilibrium between quiescence, self-renewal,
migration and differentiation of HSCs at steady-state and in response to injuries
and emergencies. A growing body of evidence indicates that HSCs in different
activation states and differentiation stages are maintained in distinct BM niches
[76, 77]. These niches are comprised of a complex integrated system of nonhematopoietic and hematopoietic cells that secrete factors and express receptors
that regulate maintenance, proliferation, retention and quiescence summarized
below in Figure 8[78].
Earlier studies revealed the primary location of HSC niche to be the
“endosteal niche” closest to the surface of the bone[79-81], however studies have
since then identified multiple niches including the “sinusoidal/vascular niche” and
more recently the “arteriole niche.” It is now currently accepted that distinct HSCs
niches are located throughout the bone marrow[82]. Homed long-term
repopulating HSCs preferentially localize to the endosteal niche proximal to
trabecular bone surface [83] while the most quiescent HSC localize to the oxygenlow arteriolar niches in the endosteum [84] and the activated HSC migrate to
sinusoidal niches located closer to the central artery and vein (Figure 7B)[85].
The various cell types implicated in regulating HSC activity, include
perivascular mesenchymal stem cells (MSCs), endothelial cells, osteoblastic
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lineages, adipolineage cells, sympathetic nervous system (SNS) nerves, nonmyelinating Schwann cells, macrophages, megakaryocytes and regulatory T
(Treg) cells. Osteoblasts were the first to be identified as a BM niches cell. Elegant
confocal and other modern imaging techniques now show that osteoblast do not
directly interact with HSCs but are often found proximal to HSC and the ablation
of osteoblast significantly reduces HSC maintenance. This is thought to be
mediated by osteopontin.
BM endothelial cells line the interior of all blood vessels and produce various
factors, such as Notch ligands, CXCL12, SCF and pleiotrophin, that regulate the
activity of HSCs. There are two main types of endothelial populations in the BM,
the arteriolar endothelial cells (AECs) and sinusoid endothelial cells (SECs). AECs
line the arterioles and secrete nearly all detectable endothelial-derived SCF in the
BM. Arterioles are less permeable and therefore more hypoxic whereas sinusoid
capillaries are leakier and have more oxygen. HSC isolated from areas rich in
AECs are quiescent and contain low levels of ROS whereas those isolated from
areas rich in SECs have increased ROS levels, leading to their activation and
augmenting their differentiation and migration. Other niche components and their
regulator function are summarized in Figure 8 below.
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Figure 8. Summary of niche cells and their contribution to HSC maintenance.
Perivascular mesenchymal stem cells (MSCs), endothelial cells, osteoblasts,
adipolineage cells, sympathetic nervous system (SNS) nerves, non-myelinating
Schwann cells, macrophages, megakaryocytes and regulatory T (Treg) cells
collaboratively work together to release factors osteopontin, CXCL4, TGF-β,
Adenosine that stimulate HSC quiescence, SCF, CXCL12, pleiotrophin that maintain
HSCs, express membrane-bound CXCL12, VCAM1 that retain HSC , Notch ligands
and FGF1 that promote HSC proliferation and other factors that are involved in HSC
regulation.
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Signaling pathways involved in HSC regulation
Extrinsic modulators (including many cytokines, growth factors, and
metabolites) and intrinsic regulators (such as certain transcription factors, cell
cycle regulators, metabolites and molecular modulators) control HSC fate through
numerous signaling pathways.
The chemokine receptor CXCR4 and its ligand the chemokine stromal cellderived factor-1 (SDF-1, also known as CXCL12) are vital for HSC quiescence,
BM retention and protection against oxidative stress [86-89]. Deletion of CXCR4
or CXCL12 resulted in perinatal lethality; however, the analysis of conditionally
deficient CXCR4 or CXCL12 mice led to a reduction in HSC numbers, expansion
in multipotent progenitors (only in CXC12 deficient mice) and altered localization
of HSC (absent along the endosteal surface, but predominantly in the
perisinusoidal space) [86-89].
Tie2 is a receptor tyrosine kinase robustly expressed on a portion of HSC and
endothelial cells. While Tie2 has been shown to be expressed on LT-HSC, Tie2
ablation studies show that it is dispensable for fetal liver HSC maintenance but
plays a crucial role in adult HSC maintenance along with its ligand angiopotin1(Ang-1) [90, 91]. The Tie2/Ang-1 axis promotes adhesion of Tie2+ HSCs to
fibronectin (FN) and collagen (COL) anchoring HSCs to their quiescent niche and
protecting the HSC compartment from myelosuppressive stress [90, 91].
Notch signaling is vital for generating hematopoietic stem cells from endothelial
cells during definitive hematopoiesis[92], however its role in adult HSC
maintenance is controversial due to various conflicting results obtained in several
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studies[93]. There are four Notch receptors (Notch1, 2, 3, and 4) expressed on
HSCs and five membrane Notch ligands (Delta-like1, 3, and 4 and Jagged1 and
2) expressed on endothelial cells in the BM. Notch signaling is highly active in
HSCs and reduced in differentiated cells. Pan-inhibition of all canonical Notch
signaling approach mediated by the overexpression of a dominant negative form
of Mastermind-like 1 (dnMAML1) resulted in a severe reduction of mouse LT-HSC
through accelerated differentiation[94] Demonstrating the importance of notch
signaling in LT-HSC maintenance.
Fetal stem cells are actively cycling and expanding and highly metabolically
active to meet their energy requirements[62, 73-75]: whereas, adult stem cells
typically maintain a metabolic inactive state to preserve long-term self-renewal
capacity for tissue maintenance and prevent HSC exhaustion[95-99]. Quiescent
HSCs primarily rely on anaerobic glycolysis to minimize mitochondrial oxidative
phosphorylation (OXPHOS) and ROS production[95-99]. During hematopoietic
recovery, HSCs shift their metabolic activity from glycolysis to OXPHOS, which
provides energy and increases the production of ROS and other metabolites that
stimulate signaling pathways leading to differentiation into different lineage-biased
multipotent progenitors (MPP). Metabolic activity increases during differentiation
and drastically decreases as terminally-differentiated mature populations are
achieved[96]. Hypoxia and master transcription regulator, Myc, plays an important
role in regulation HSC metabolism and therefore HSC cell fate[99].
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Abnormal hematopoiesis and hematological disorders
The balance between differentiation and self-renewal is tightly regulated to
ensure hematopoietic homeostasis throughout life. Excessive differentiation with
insufficient self-renewal depletes the HSC pool and causes HSC exhaustion
(Figure 9). Restricted differentiation with unrestrained self-renewal can lead to
myeloproliferative diseases or leukemia (Figure 9). Extreme stress or injury can
lead to diminished HSC and mature cell populations that will result in bone marrow
failure.

Figure 9. Consequences of abnormal hematopoiesis.
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CHAPTER TWO:
LIGAND-MEDIATED PROTEIN DEGRADATION REVEALS FUNCTIONAL
CONSERVATION AMONG SEQUENCE VARIANTS OF THE CUL4-TYPE E3
LIGASE SUBSTRATE RECEPTOR CEREBLON
A note to the reader: this chapter has been previously published in a research article in
Journal of Biological Chemistry, Akuffo et. al 2018[100]
Introduction
CRBN binds to thalidomide, and other immunomodulatory drugs, including
lenalidomide (Len) and pomalidomide (Pom), and is one of many DDB1 and CUL4associated factors (DCAFs) that target specific protein substrates for ubiquitylation and
proteasome-mediated degradation by the DDB1-CUL4A-Roc1-RBX1 E3 ubiquitin ligase
complex [14, 28, 101]. Despite their teratogenic properties [6], immunomodulatory
compounds have antineoplastic activity in multiple myeloma [10], myelodysplastic
syndrome (MDS) associated with a somatically acquired deletion in chromosome 5
(del(5q) MDS) [18] and B cell malignancies [12, 102, 103] based on the substrates that
are selected for proteosomal destruction by the bridging actions of these small molecules
[14, 35, 101, 104-106]. Len, Pom and a newer derivative CC-122 (avadomide) [107] also
potentiate the activation of T-cells. Though this function has been studied less thoroughly,
it is thought that the drug-induced proteosomal-mediated degradation of transcriptional
repressors of T-cells, Ikaros and Aiolos, may be necessary for this response in addition
to their defined role in antineoplastic activity [33, 34, 108]. Unlike human cells, mouse
cells are resistant to these compounds including antiproliferative multiple myeloma[109]
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and thalidomide-associated teratogenicity[110]. While the overall amino acid sequence
of mouse CRBN is highly conserved (Figure 10), and it forms the DDB1 interaction [28],
minor species-related sequence variations in the thalidomide binding domain (TBD) of
CRBN are thought to lead to non-conserved drug binding or altered E3-ligase recruitment
functions. A single amino acid substitution, Val388 which is changed to isoleucine in
mouse (Ile391), has been reported to render mouse CRBN unable to degrade Ikaros,
Aiolos, and CK1α binding through a β-hairpin-loop motif that is recognized only when
CRBN is complexed with the immunomodulatory drugs [31]. Therefore, dysfunctional
drug-induced substrate requirement possibly mediates drug resistance [31]. Thus far,
conservation of mouse CRBN’s E3-ubiquitin ligating function has not been definitely
shown due to this loss of function as the native ligands that are regulated through this
pathway are poorly defined. Moreover, drug binding affinity due to the V388I variant has
not been studied in detail. A better understanding of this defect is important for future drug
discovery efforts aimed at controlling intracellular protein degradation and understanding
CRBN’s endogenous role as an E3-ubiquitin ligase substrate receptor.
Here, we focused our analysis on non-primate CRBN. Using drug binding assays
to several CRBN sequence variants, we investigate if these structural changes are likely
to result in functional inactivation. We focused on CRBN’s substrate recruiting function in
mouse and human T-cells, as this is poorly studied and important for defining applications
in immune therapy. Both the Bradner and Crews laboratories conjugated established
chemical inhibitors of bromodomain and extraterminal domain (BET) family members, to
a thalidomide analog to promote the CRBN-dependent degradation of BRD4[51, 52]
Linkage of the BET-binding ligand (JQ1 or OTX-015) to an IMiD® redirects CRBN-E3
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ligase activity toward BRD4 allowing for analysis of different substrates through a similar
TBD-dependent mechanism (Figure 4B). Moreover, the E3-ubiquitin protein targeting
approach, coined Proteolysis Targeting Chimera (PROTAC)[46, 50, 111], may be broadly
applied clinically and experimentally to study the function of proteins that are difficult to
target and in cells that are insensitive to genome editing techniques. Here, we use a
PROTAC probe to investigate cellular engagement of an immunomodulatory drug to
mouse CRBN. Collectively, our findings are important to understand sequence variants
of CRBN and provide the first investigation of the E3-ubiquitin ligase substrate
conjugating function of CRBN in a non-primate vertebrate model.

Results
Thalidomide binding domain of CRBN has a conserved immunomodulatory
compound binding motif
First, we studied the sequence variants of CRBN in more detail. Based on crystal
structures, immunomodulatory compounds bind to a conserved pocket within the Cterminal TBD of CRBN (Figure 10A)[13, 112]. These interactions are governed by
hydrogen bonding, aromatic quadrupole, and Van der Waals (VDW) interactions. Analysis
of the X-ray crystal structures of CRBN (human (hCRBN), mouse (mCRBN) and chicken
(gCRBN)) in complex with thalidomide, Len, and Pom, respectively (Figure 10A) shows
negligible variations of root mean square deviation (RMSD) between the inhibitor poses.
Thus, an in-depth theoretical investigation of the molecular binding mechanics of
immunomodulatory compounds in complex with CRBN was conducted to explore
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possible differences in drug interactions between mouse and human CRBN caused by

Cys366

Glu377

Val388

Ser369

Val360

Ile391

induced fit or protein flexibility.

Figure 10. Structure of cereblon is conserved across different species. (A) Ribbon
overlays of human (purple, PDB 4TZ4), chicken (blue, PDB 4CI2) X-ray crystal structures
and post-MD structure of mouse (yellow, PDB 4TZ4) cereblon. Human
immunomodulatory drug binding site residues His378, Trp380, Trp386, Phe402 and
ligands thalidomide (yellow), lenalidomide (green) and pomalidomide (blue) shown for
reference. (B) Superposition of ligand poses of lenalidomide (green) for the post-MD
29

equilibrated systems of the CRBN thalidomide binding site after induced fit docking (IFD)
for hCRBN (red), hmCRBN (green), gCRBN (orange), shown with the post-MD
equilibrated protein structure of hCRBN (red) shown for reference. (C) Overlays of human
and mouse cereblon shows non-conserved residues Ile391 for mCRBN (human Val-388);
Val-380 for mCRBN (human Glu-377) (mouse shown in italic font). (D) The CRBN protein
sequences from diverse vertebrate species that correspond to the human thalidomide
binding site were aligned using Clustal Omega [2]. Positions that are at least 90% identical
are shaded in black and similar residues are shaded in gray. Shading in other colors
highlight sequence diversity at three positions: Cys366, Glu377 and Val388 in human
(above) and Ser369, Val380 and Ile391 in mouse (below). Arrows indicate cysteines
involved in forming disulfide bridges. Sequences include: thirteen primates (human,
NP_001166953.1, common chimpanzee, XP_001140433.1; western lowland gorilla,
XP_004033566.1; Sumatran orangutan, NP_001127555.1; northern white-cheeked
gibbon, XP_012357648.1; rhesus macaque,
NP_001182576.1; olive baboon,
XP_003894216.1; green monkey, XP_007983240.1; squirrel monkey, XP_010336170.1;
common marmoset, XP_008980298.1; Philippine tarsier, XP_021562663.1 ; gray mouse
lemur, XP_020139859.1 ; Sunda flying lemur, XP_008581608.1), five non-primate
mammals
(mouse,
NP_067424.2;
rat,
NP_001015003.1;
domestic
dog,
XP_005632293.1; cow, NP_001068995.1; Florida manatee, XP_012409572.1), one
marsupial (gray short-tailed opossum, XP_001374178.2), one reptile (American alligator,
XP_006263115.1), two birds (chicken, XP_004944767.1; zebra finch, XP_012429169.1),
one amphibian (Xenopus, NP_001008192.1), one lobe-finned fish (West Indian Ocean
coelacanth, XP_006001868.1), two ray-finned fish (Spotted gar, XP_006630756.1;
zebrafish, NP_001003996.1) and one cartilaginous fish (whale shark, XP_020385559.1).
For molecular dynamics (MD), simulations of the crystal structures of hCRBN (PDB
4TZ4)[112] and gCRBN (PDB 4CI1, 4CI2, and 4CI3)[112] in complex with DNA damagebinding protein 1 (DDB1) were used. The crystal structure of mCRBN (PDB 4TZC and
4TZU)[13] is monomeric and truncated to contain only the TBD (108 defined residues
compared to 380 defined residues for hCRBN and gCRBN) and is not suitable for
computational modeling. The amino acid differences in mouse CRBN (when compared
to human) include C366S, E377V (which may be specific to rodents) and V388I (Figure
10D). Therefore, to further increase sampling and determine any structural dependence
on these residues, the original hCRBN sequence of the equilibrated representative
structure was mutated to the mouse sequence. The mCRBN analog and hmCRBN hybrid
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developed from the hCRBN system is capable of reproducing the crystal ligand poses of
mCRBN (PDB 4TZC and 4TZU) with minimal conformational deviation (Figure 10C) and
was used for modeling purposes. Binding modes do not appear to differ between models
and compounds as there are no significant differences in RMSD calculations between Xray crystal binding poses (Table 4) and post-MD equilibrated models (Figures 10B and
C). Induced fit docking (IFD) also predicts no observable difference in binding affinity
between models and compounds (Table 4). All poses are within 1.8 Å RMSD, which is
the expected threshold for the IFD protocol [113].
Although

Val388

of

hCRBN

recruits

Ikaros,

Aiolos,

and

CK1α

upon

immunomodulatory compound binding [31], the side chain is > 6 Å away from the
immunomodulatory drug, and it is thus unlikely to alter binding affinity to the drugs. The
second distinct amino acid is Glu377, which in the mouse is Val380, and could establish
a weak hydrogen bond with Len’s amino group. However, hydrogen bond analysis (Figure
11) of MD simulations suggests minimal interaction occurs between this residue and
bound immunomodulatory drugs, mainly due to backbone dihedral strain tending to force
the charged carboxyl moiety away from the binding site.
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Table 4. RMSD Calculations.

Thal

Len

Pom

hmCRBN

hCRBN

hCRBN

gCRBN

gCRBN

mCRBN

mCRBN

Post MD

Post MD

Crystal

Post MD

Crystal

Post MD

Crystal

Glide Score

-11.040

-11.049

-10.789

-11.408

-10.724

-10.082

-9.344

Emodel

-81.796

-83.437

-78.630

-77.239

-79.853
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-

-

-
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-77.976
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0.7384c

1.7233c
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1.0053d

-

-

Glide Score

-11.200
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-10.800

-10.256

-11.634
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Emodel
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-86.330

-81.008

-80.357

-84.483

-51.789

-58.872

-

-

-

1.7592e

0.9482e

4.6167f

2.8715f

Pose RMSD

a

Pose RMSD calculated using PDB 4CI1 for comparison.
Pose RMSD calculated using PDB 4TZC for comparison.
c
Pose RMSD calculated using PDB 4TZ4 for comparison.
d
Pose RMSD calculated using PDB 4CI2 for comparison.
e
Pose RMSD calculated using PDB 4CI3 for comparison.
f
Pose RMSD calculated using PDB 4TZU for comparison.
b

32

Figure 11. RMSD profiles of hCRBN, mCRBN, gCRBN & hmCRBN. (A) RMSD profiles
of hCRBN. Profiles were created using backbone atoms and were calculated with
hCRBN-DDB1 complex (Bottom Graph), hCRBN alone (Middle Graph), and binding site
residues N335 to A421 (Top Graph). All measurement units are in Angstroms. (B) RMSD
profiles of mCRBN. Profiles were created using backbone atoms and were calculated
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with all hCRBN residues (Bottom Graph), binding site residues N335 to A421 (Middle
Graph), and residues (357, 377, 379-383, 388-390, 401, 402, 404) located 6 Å away from
the ligand (Top Graph). All measurement units are in Angstroms. (C) RMSD profiles of
gCRBN. Profiles were created using backbone atoms and were calculated with hCRBNDDB1 complex (Bottom Graph), gCRBN alone (Middle Graph), and binding site residues
N337 to A423 (Top Graph). All measurement units are in Angstroms. (D) RMSD profiles
of hmCRBN. Profiles were created using backbone atoms and were calculated with
hmCRBN-DDB1 complex (Bottom Graph), hmCRBN alone (Middle Graph), and binding
site residues N335 to A421 (Top Graph). All measurement units are in Angstroms. (E) Rg
Profiles of hCRBN. Profiles were created from all atoms and were calculated with hCRBNDDB1 complex (Bottom Graph) and hCRBN alone (Top Graph). All measurement units
are in Angstroms. (F) Rg Profiles of mCRBN. Profiles were created from all atoms. All
measurement units are in Angstroms. (G) Rg Profiles of gCRBN. Profiles were created
from all atoms and were calculated with gCRBN-DDB1 complex (Bottom Graph) and
hCRBN alone (Top Graph). All measurement units are in Angstroms. (H) Rg Profiles of
hmCRBN. Profiles were created from all atoms and were calculated with hmCRBN-DDB1
complex (Bottom Graph) and hmCRBN alone (Top Graph). All measurement units are in
Angstroms. (I) RMSF Profile of hCRBN. Profiles were created using backbone atoms and
were calculated with hCRBN alone (DDB1 RMSF available upon request). Binding site
residues N335 to A421 displayed as dashed line. All measurement units are in
Angstroms. (J) RMSF Profile of mCRBN. Profiles were created using backbone atoms of
mCRBN. Binding site residues N335 to A421 displayed as dashed line. All measurement
units are in Angstroms. (K) RMSF Profile of gCRBN. Profiles were created using
backbone atoms and were calculated with gCRBN alone (DDB1 RMSF available upon
request). Binding site residues N337 to A423 displayed as dashed line. All measurement
units are in Angstroms. (L) RMSF Profile of hmCRBN. Profiles were created using
backbone atoms and were calculated with hmCRBN alone (DDB1 RMSF available upon
request). Binding site residues N335 to A421 displayed as dashed line. All measurement
units are in Angstroms. (M) Potential energy profile of hCRBN simulation. Multiple linear
fits were characterized to determine asymptotic behavior by minimizing slope. (N)
Potential energy profile of mCRBN simulation. Multiple linear fits were characterized to
determine asymptotic behavior by minimizing slope. (O) Potential energy profile of
gCRBN simulation. Multiple linear fits were characterized to determine asymptotic
behavior by minimizing slope. (P) Potential energy profile of hmCRBN simulation. Multiple
linear fits were characterized to determine asymptotic behavior by minimizing slope.

Immunomodulatory compound binding is conserved in CRBN sequence variants.
Amino acids in mouse CRBN-TBD at Val380 (equivalent to human Glu377) and
Ile391 (equivalent to humanVal388) (Figure 12A-C) appear to have no relevance in the
structure or corresponding immunomodulatory drug binding interaction based on
theoretical modeling. To test the effects of these two non-conserved amino acids on
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binding affinity, the recombinant human TBD motif (residues 319-425) was expressed in
E. coli and mutated to the mouse variants (Figure 12A-C). Immunomodulatory drug
binding was then analyzed using two distinct assays, intrinsic tryptophan fluorescence
assay (IF) (Figure 12D-G) and isothermal titration calorimetry (ITC) (Figure 12H-K). The
C366S amino acid mutation was not studied in binding assays as it is more than 20 Å
away from the immunomodulatory drug binding pocket. The TBD is structurally stabilized
by four cysteine residues (Cys323, Cys326, Cys391 and Cys394) that coordinate a single
zinc ion [13, 112], located ~18 Å from the drug interacting site. To gain insights on the
role of zinc, mutations in the CXXC domain of the TBD were also generated. Mutating
any of the cysteine residues resulted in insoluble protein that aggregated in inclusion
bodies (data not shown). This is indicative of misfolding due to loss of Zn2+ ion
coordination. To rule out improper folding or destabilization, a zincon assay [114] was
performed on purified protein of all expressed recombinant CRBN-TBD proteins. These
analyses revealed a 1:1 stoichiometric ratio of Zn2+ bound to the TBD recombinant protein
(data not shown).
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Figure 12. Human and mouse CRBN binds IMiD®s with similar affinities. (A)
Sequence alignment of human CRBN and human to mouse mutations. Mutations
introduced to convert human to mouse are highlighted in red. (B) IMiD® interaction in the
hydrophobic binding pocket. (C) Lenalidomide (green) interacts with the TBD site (gray)
through hydrogen bonds (dashed black lines) with backbone residues His378, Ser379
and Trp380 VDW interactions (dashed green lines) occur with the side chains of Trp380,
Trp386, Trp400, and Tyr402 (mouse: Trp383, Trp389, Trp403, and Phe405). The two
residues differing between the human and the mouse proteins are highlighted in cyan.
Titration of human TBD (D) wild-type, (E) E377V, (F) V388I, and (G) E377V/V388I (hmCRBN-TBD) to lenalidomide (red), pomalidomide (green), thalidomide (blue) and
pthalimide (black) by intrinsic tryptophan fluorescence assay. KD values were calculated
based on the magnitude of fluorescence differences (1-F/F0). (H-K) Isothermal titration
calorimetry saturation curve using lenalidomide (LEN) for human TBD and mutants
Moreover, protein secondary structure consistent with proper folding was also
evident using circular dichroism (data not shown). Both IF (Figure 12D-G) and ITC (Figure
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12H-K) analyses demonstrated similar KD values at equilibrium for thalidomide and the
immunomodulatory compounds tested in binding to wild-type, E377V, V388I, and
E377V/V388I (hm)-CRBN-TBD (Table 5) with no binding observed by pthalimide (Figure
13I-L) used as a negative control.
Table 5. Binding affinity (KD, (µM)) of immunomodulatory compounds to WT and mutant
human CRBN-TBD determined using ITC and Fluorescence intensity (FI) assay.
dBET1
TBD

Assay

Lenalidomide

Pomalidomide

Thalidomide

Phthalimide

ITC

11 ± 3

16 ± 4

65 ± 40

nb

np

FI

13 ± 2

16 ± 3

38 ± 12

nb

16 ± 2

hCRBN-

ITC

22 ± 3

35 ± 8

37.4 ± 10

nb

np

H378A

FI

27 ± 4

22 ± 6

74 ± 20

nb

np

hCRBN-

ITC

nb

nb

nb

nb

np

W380A

FI

nb

nb

nb

nb

np

hCRBN-

ITC

9.6 ± 2

35 ± 9

97 ± 100

nb

np

E377V

FI

22 ± 2

30 ± 7

36 ± 8

nb

np

hCRBN-

ITC

10 ± 1

28 ± 7

43 ± 20

nb

np

V388I

FI

14 ± 4

16 ± 4

39 ± 1

nb

13 ± 2

hmCRBN-

ITC

14 ± 2

8±2

34 ± 2

nb

np

E377V/V3

FI

13 ± 3

19 ± 4

30 ± 8

nb

np

hCRBN

88I

Data represents mean ± standard deviation. TBD=thalidomide binding domain of CRBN,
ITC=isothermal titration calorimetry, FI=fluorescence intensity, nb=non-binding, np=not
performed
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Figure 13. Binding affinity of IMiD®s to TBD variants by ITC. ITC binding curves of
pomalidomide (A-D), thalidomide (E-H), pthalimide (I-L) with wild-type and mutant CRBN
TBD protein

To assess the impact of binding pocket residues, Ala mutations of two residues
were generated (Table 5) (7, 26, 27) to test the impact of H-bond formation and
hydrophobic interaction with Trp380. Trp380A mutation completely abolished ligand
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interactions. Although His378 forms two H-bonds with the glutarimide ring (Figure 12C),
mutating this residue to Ala did not impact binding. This suggests that the backbone
carbonyl of H378A retains the H-bond interaction with the NH group of the glutarimide
ring. To further probe the role of His378 side chain in immunomodulatory drug binding,
we conducted a pH-dependence study to measure the binding affinity of Len to CRBNTBD by ITC. The KD values measured at pH 4.5, 5.5, 6.5 and 7.5 are 21.4 ± 3, 23.7 ± 8,
23.8 ± 7 and 11.3 ± 2 µM, respectively. Thus, protonation and deprotonation of the His378
imidazole group has no impact on immunomodulatory drug binding to the TBD.

N-terminal stabilization of CRBN-immunomodulatory compound interactions.
Finally, we compared binding affinities of Len to CRBN-TBD and full-length CRBNDDB1 protein complex using ITC to assess the impact of residues outside of the TBD.
The full-length CRBN-DDB1 complex displayed a KD value of 0.64 µM ± 0.24 µM (pH 7.0)
(Figure 14A). This affinity is similar to published data using a fluorescence polarization
(FP)-based assay (32). Moreover, these results are consistent with a single binding site
within the protein complex. To gain more insight on immunomodulatory compound
binding to CRBN-TBD, we synthesized N-methyl-Len as a negative control, where the Nmethyl group of the glutarimide ring is predicted to cause steric hindrance in the binding
pocket and lacks the key H-bond donor to His378. As expected, N-methyl-Len did not
bind to either the CRBN-TBD or CRBN-DDB1 complex (Figure 14B), as measured by
ITC, indicating that the complex-drug interaction is mediated predominantly by the
glutarimide binding pocket of the TBD. Interestingly, the binding affinity of Len to the
CRBN-TBD is about 30-fold lower than the full-length CRBN-DDB1 complex. Moreover,
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full-length CRBN and CRBN-TBD have endothermic and exothermic reactions,
respectively. Therefore, residues in the full-length protein appear to augment proteinligand interactions in the binding pocket.

Figure 14. Lenalidomide binds to the TBD and CRBN-DDB1 protein complex. ITC
binding curves of lenalidomide (A, C) and N-methyl-lenalidomide (B,D) titrated with (A,
B) CRBN-DDB1 complex and (C,D) CRBN-TBD. (E and F) Schematic view of
lenalidomide interaction in the binding pocket of full-length human cereblon; human fulllength CRBN (salmon) and DDB1 (blue) with bound lenalidomide (magenta) (PDB
5FQD), superimposed with mouse TBD-CRBN (cyan) (PDB 4TZU). Hydrogen bonds
and hydrophobic interactions are shown in red and black dashed lines, respectively.
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Resistance of mouse cells to immunomodulatory compounds.
Comparative analyses of CRBN sequences from representative vertebrate species
revealed that Ile391 is conserved among many non-primate mammals (mouse, rat, dog,
manatee and opossum), birds (chicken and zebra finch), reptiles (alligator), amphibians
(Xenopus), bony fish (zebrafish and spotted gar) and cartilaginous fish (whale shark)
(Figure 10D)[2]. Interestingly, both chicken and zebrafish are susceptible to thalidomideinduced teratogenicity despite expressing the Ile391 variant [28]. In contrast, Val388 is
present in all examined primate sequences (human, chimpanzee, gorilla, orangutan,
gibbon, macaque, baboon, green monkey, squirrel monkey, marmoset, tarsier and Sunda
flying lemur) with the exception of gray mouse lemur, which encodes Ile in this position
(Figure 10D). Therefore, Val388 is a recently derived feature present in most primates.
Immunomodulatory drug-induced ubiquitin-mediated degradation of Ikaros and
Aiolos (encoded by IKZF1 and IKZF3, respectively)[14, 115] appears sufficient to
augment IL-2 production by T-cells[116] in the absence and presence of anti-CD28 costimulation [108, 117, 118]. In Len-treated human T-cells stimulated with anti-CD3ε
antibody to cross-link the T-cell receptor (TCR), levels of IL2 mRNA (Figure 15A) and
protein (Figure 15B) were significantly increased relative to DMSO-(vehicle) treated cells.
Comparing purified human (Figure 16A) and mouse T-cells (Figure 16B) pretreated with
vehicle or 10 μM Len, only human T-cells displayed the expected Len-induced increase
in IL-2 when stimulated in the absence (Figure 16A,B) or presence (Figure 15C-D) of antiCD28 antibody using doses of anti-CD3ε that ranged from 0.01 – 10 µM.
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Figure 15. Lenalidomide treatment induces IL-2 production and proliferation in T
cells. (A) Relative IL-2 mRNA production with increasing concentrations anti-CD3 (0.01
– 10 μg/mL) stimulation. (B) IL-2 secretion by ELISA in unstimulated cells and after
treatment with anti-CD3 (5μg/mL) and anti-CD28 (1 µg/ml) with increasing concentrations
of lenalidomide. (C) Proliferation in human T cells and (D) mouse T cells treated with
DMSO (vehicle) or lenalidomide (10 μM) measured by S-phase transition as indicated by
incorporation of bromodeoxyuridine (BrdU) with detection by flow-cytometry in cells
stained for CD8+ surface expression,
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Thalidomide, Len and Pom’s antiproliferative effects in multiple myeloma cell lines also
reportedly differ based on the presence of mouse CRBN[31, 32, 109]. In U266 (Table 6),
H929 (Table 6), and MM1.S multiple myeloma cell lines (Figure 16C, Table 6), the
antiproliferative effects (IC50s) of Pom ranged from 0.05 to 0.51 µM and for Len from 1.5
to 10 µM. In contrast, the mouse multiple myeloma cell line 5TGM1 was resistant to
immunomodulatory drugs (Figure 16D, Table 6). Further, Ikaros protein expression was
unaffected in primary mouse T-cells compared to almost completely depleted in human
cells (Figure 16E) as predicted from previous structural and functional studies in multiple
myeloma cell lines and in the Ba/F3 mouse lymphoma cell line [31, 35].

Table 6. IC50 (µM) of Multiple Myeloma Cell Lines.
Drug

H929

U266

MM1.S

5TGM1

Lenalidomide

5.13

10.0

1.48

>>100

0.046

0.51

0.099

>>100

(Len)
Pomalidomide
(Pom)

H929, U266 and MM1.S are human multiple myeloma cell lines while 5TGM1 is a mouse
multiple myeloma cell line. IC50 (µM) calculated as follows: log(inhibitor) vs response
based on variable slope (four parameters), Y=bottom (best fit value) + (100Bottom)/1+10^((LogEC50-X)*n)).
IC50= (100-Bottom – 1) 1/-n x EC50
50 - Bottom
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Figure 16. Mouse cells are resistant to immunomodulatory drugs. (A) T cells purified
from healthy donor peripheral blood mononuclear cells (PBMCs) or (B) from mouse
spleens of C57BL6 mice and stimulated in the presence of increasing concentrations of
anti-CD3ε antibody in the presence of 10 μM lenalidomide (Len) or vehicle control
(DMSO) without anti-CD28. IL-2 production was determined from the culture supernatant
by ELISA. (C) The human MM1.S or (D) mouse 5TGM1 multiple myeloma cells were
cultured for 7 days with increasing concentrations of lenalidomide (Len), pomalidomide
(Pom) and vehicle (DMSO). Percentage relative cell viability is shown. (E) Western blot
analysis of Ikaros, CRBN and β-actin (loading control) in human and mouse T cells
stimulated with anti-CD3ε 5 μg/mL + 1 μg/mL anti-CD28 antibody for 24 h with DMSO, 10
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and 20 μM lenalidomide and pomalidomide. Results are representative of three
independent experiments. Statistical analysis was conducted using ANOVA, followed by
Dunnett’s multiple comparison test. *=p<0.05, ***=p<0.001

Acquired ubiquitin-proximity ligation in mouse cells establishes conserved ligase
functions of mouse and human CRBN variants.
The substrate recruiting function of CRBN was then investigated using dBET1,
which maintains the CRBN-TBD targeting domain, but switches the substrate-recruitment
domain to recognize BRD4 and other JQ1-associated targets [51]. Using IF (Figure 17A),
the saturation binding curves for dBET1 is similar to that of Len, whereas, as expected,
JQ1 alone does not bind to the CRBN-TBD. The structures of dBET1 and N-methyldBET1 (used as a negative control based on the results of N-methyl-Len) are provided in
Figure 17B to show the CRBN and BET targeting groups. Moreover, N-methyl-dBET1
confirms that this analog is interacting with similar residues in the TBD. Next, the function
of dBET1 in activated human T-cells was assessed and results are shown in Figure 17CF, statistical analysis provided in Table 7. Unlike Len and Pom which activate T-cells,
BRD4 and c-Myc inhibition is expected to induce cell death or functionally repress these
cells as they are critical mediators of T-cell proliferation and survival [119, 120]. Relative
viability of activated T-cells is reduced by dBET1 treatment compared to DMSO and is
more active relative to treatment with increasing doses of JQ1 (Figure 17C) suggesting
that growth suppression by the heterobifunctional conjugate is superior to JQ1, as shown
previously in leukemia cells [51].
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Figure 17. Functional activity of lenalidomide, JQ1 and dBET1 in human T cells and
binding affinities of JQ1, dBET1 and Len to human CRBN. (A) Saturation binding
curves of human TBD wild-type titrated with lenalidomide (Lenalidomide, KD=15.6±2.2),
JQ1 (no binding), dBET1 (KD=26.0±2.1), N-methyl-dBET1 (no binding) by fluorescence
assay (see also Table 1 for a summary of all KD values). (B) Structure of dBET1 and Nmethyl-dBET1. (C) Human T-cells purified from peripheral blood mononuclear cells
(PBMCs) from healthy donors and stimulated with anti-CD3ε /CD28. At the time of TCR
stimulation, DMSO (vehicle control), indicated concentrations of JQ1 and dBET1, 10 μM
lenalidomide (Len) and 10 μM pomalidomide (Pom) were added to the cell cultures. Cell
viability was determined after 72 h by flow cytometry using Zombie NIRTM staining. (D)
Western blot analysis for expression of BRD4, CRBN, c-Myc and vinculin in human T
cells stimulated with anti-CD3ε /CD28 and treated simultaneously with vehicle (DMSO,
0.1%), JQ1, dBET1 (10µM) and N-methyl-dBET1 (10 µM) for 48 h. Unstimulated cells are
not shown in D. (E) c-Myc expression by flow cytometry (histogram data) is shown
following 48 hrs stimulation with anti-CD3ε /CD28. Drug treatments and doses are
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indicated. Expression of c-Myc requires stimulation based on comparison with
unstimulated cells (unstim).Values represent % positive relative to unstimulated cells
based on gate (dotted line). (F) Quantification of flow data shown in (E) represented as
% of DMSO. Bar height is the mean of individual values shown representative of three
independent experiments. Error bars represent standard deviation from an exemplary
experiment. (G) Unstimulated (unstim) or anti-CD3ε /CD28 stimulated T-cells were
treated with 10 μM Len, 10 μM Pom, and indicated doses of JQ1 or dBET1. Enzymelinked immunosorbent assays (ELISA) were used to quantify IL-2 concentrations (pg/mL)
from supernatants harvested at 48 hrs. Results shown are representative of three
independent experiments. Bar height represents mean of individual values and error bars
represent standard deviation from an exemplary experiment. Results of statistical
analysis provided in Table 7.
Importantly, decreased BRD4 protein expression is only evident with dBET1
treatment, while both dBET1 and JQ1 suppress the activation of c-Myc protein expression
by Western blot analysis (Figure 17D) and flow cytometry (Figure 17E, summary of data
Figure 17F), as expected, through BRD4 functional repression. Notably, the effect on
BRD4 is reversed by incubation with N-methyl-dBET1 at doses of 0.1 – 10 μM.
Repression of c-Myc at very high doses of N-methyl-dBET1 is consistent with activity of
the JQ1 targeting molecule (Figure 17D and F). From these results, we conclude that
human T-cells respond to dBET1 through interactions that are mediated by the
hydrophobic pocket of the CRBN-TBD. Finally, the suppressive effects observed with
dBET1 treatment shows that the CRBN targeting molecule in this compound is no longer
activating IL-2 as shown in Len and Pom (Figure 17G).
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Table 7. Statistical analysis of Human T cells treated with IMiD®s, JQ1 and dBET1

Relative Viability to DMSO
(%)

Relative c-Myc+ cells to
DMSO (%)

IL-2 Concentration (pg/mL)

Comparisons
DMSO vs. JQ1 0.1
DMSO vs. JQ1 1
DMSO vs. JQ1 10
DMSO vs. dBET 0.1
DMSO vs. dBET 1
DMSO vs. dBET 10
DMSO vs. LEN
DMSO vs. POM
JQ1 0.1 vs. dBET 0.1
JQ1 1 vs. dBET 1
JQ1 10 vs. dBET 10

P value
0.0035
0.0001
0.0001
0.0001
0.0001
0.0001
0.0794
0.2305
0.0001
0.0001
0.0001

Summary
**
***
****
****
****
****
ns
ns
****
****
****

DMSO vs. Naïve
DMSO vs. JQ1
DMSO vs. dBET 0.1
DMSO vs. dBET 1
DMSO vs. dBET 10
DMSO vs. dBET 50
DMSO vs. M-dBET 0.1
DMSO vs. M-dBET 1
DMSO vs. M-dBET 10
DMSO vs. M-dBET 50

0.0001
0.0001
0.0001
0.0001
0.0001
0.0001
0.3672
0.0777
0.0016
0.0001

****
****
****
****
****
****
ns
ns
**
****

DMSO vs. Unstimulated
0.0001
****
DMSO vs. Len 10
0.0001
****
DMSO vs. Pom 10
0.0001
****
DMSO vs. JQ1 0.1
0.2527
ns
DMSO vs. JQ1 10
0.0001
****
DMSO vs. dBET 0.1
0.9997
ns
DMSO vs. dBET 10
0.0002
***
P value: * < 0.05, ** < 0.01, *** < 0.001, **** < 0.0001
Note: One-way ANOVA test and unpaired two tailed t-tests
were performed
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Next, saturation-binding curves of V388I-TBD mutant titrated with Len
(KD=15.6±2.2 µM), dBET1 (KD=26.0±2.1 µM), and N-methyl-dBET1 (non-binding control)
shows that the mode and binding affinity of dBET1 is similar to the human-TBD protein
(Table 5, Figure 18A). Mouse T-cells were purified from Crbn+/+ and Crbn-/- mice and used
to evaluate the role of mouse CRBN in BRD4 degradation (Figure 18B, C), activationinduced proliferation, viability, c-Myc and CD98 (Myc target gene) (Figure 18D-G)
expression in response to dBET1 treatment (Figure 17B). TCR stimulation with anti-CD3ε
+ anti-CD28 is required for the induction of c-myc in primary mouse T-cells (data not
shown). Both JQ1 and dBET1 suppressed c-Myc in activated T-cells, but the reduction in
protein expression of BRD4 was only observed after dBET1 treatment in Crbn+/+ mouse
T-cells consistent with proteasome engagement (Figure 18B) through a CRBNdependent mechanism. Pomalidomide treatment failed to impact BRD4 expression and
further supports redirection of CRBN’s ubiquitin-conjugating function through JQ1. To
assess whether dBET1 is interacting directly with the TBD of mouse CRBN in vivo, an
assay was performed using mouse Crbn+/+ T-cells treated with Pom in the presence and
absence of dBET1. Results shown in Figure 6C show that at high concentrations of Pom
(10-fold excess), the impact of dBET1 on c-Myc and BRD4 expression was reversed
suggesting that dBET1 is directly engaging the TBD of mouse CRBN. We next examined
proliferation (i.e., division index) measured by dilution of cell trace violet (CTV) using
methods described previously[121], expression of a c-Myc target gene (CD98), and
viability using flow cytometry (Figure 18D). Histograms (Figure 18D) and summarized
results (Figures 18E-G) show that the division index (based on CTV data) and CD98
expression (median fluoresce intensity, MFI) is induced through activation (unstimulated
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vs DMSO) and that there is a differential response to dBET1 treatment in Crbn+/+ and
Crbn-/- T-cells at 0.1 and 1 μM. The suppression of T-cells at 10 μM is likely related to be
mediated by JQ1 targeting molecule since proliferation, c-Myc-regulated CD98
expression, and viability were suppressed independent of CRBN expression. Moreover,
BRD4 degradation by dBET1 is similar in MM1.S human and 5TGM1 mouse multiple
myeloma cells confirming the conserved ubiquitin conjugating functions of CRBN (Figure
19).

Figure 18 Functional activity of lenalidomide, pomalidomide, JQ1 and dBET1 in
mouse T cells. (A) Saturation binding curves of human V388I mutant TBD titrated with
lenalidomide (Lenalidomide, KD=18±4), JQ1 (no binding), dBET1 (KD=18±3), N-methyldBET1 (no binding) by fluorescence assay (see also Table 1) (B) Mouse T cells purified
from spleens of C57BL/6j mice with homozygous deletion of Crbn and wild-type
littermates were stimulated with anti-CD3ε /CD28 in the presence of 0.1% DMSO
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(vehicle control), 10 μM pomalidomide (Pom), 10 μM JQ1 or 10 µM dBET1. Western
blots for BRD4, c-Myc, CRBN and vinculin (loading control) expression are shown. (C)
Western blot analysis showing expression of BRD4, c-Myc and vinculin from Crbn+/+ T
cells stimulated with anti-CD3ε /CD28 for 12 hrs with indicated doses of dBET1,
pomalidomide (Pom) or combined treatment. (D) Purified Crbn+/+ and Crbn-/- mouse T
cells stimulated with anti-CD3ε /CD28 and treated with 0.1% DMSO (vehicle control), 10
μM lenalidomide (Len), 10 μM pomalidomide (Pom), 10 μM JQ1 or increasing doses of
dBET1, for 72 hrs. Histogram plots from one experiment showing proliferation
(determined by dilution of CellTrace™ Violet, CTV) and CD98 expression of T cells. (E)
Proliferation index based on CTV data was used to calculate the amount of proliferation
using an algorithm available with Flowjo analysis software (Tree Star). (F) Expression
of CD98 was calculated relative to unstimulated cells using gates shown based on
mean fluorescence intensities (MFI) of T cells as shown in Figure 6(D). (G) Cell viability
was determined after 72 h by flow cytometry using Zombie NIRTM staining. Results
shown are representative of three independent experiments. Bar height represents
mean of individual values and error bars represent standard deviation from an
exemplary experiment. Results of statistical analysis provided in Table 8.
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Table 8. Statistical analysis of Crbn+/+ and Crbn -/- mouse T cells treated with IMiD®s,
JQ1 and dBET1
Crbn+/+ T cells
P value
Summary

Crbn-/- T cells
P value
Summary

DMSO vs.
Unstimulated
DMSO vs. Len 10
DMSO vs. Pom 10
DMSO vs. JQ1 10
DMSO vs. dBET1 0.1
DMSO vs. dBET1 1
DMSO vs. dBET1 10

0.0001
0.0033
0.0606
0.0001
0.0001
0.0001
0.0001

****
**
ns
****
****
****
****

0.0414
0.9997
0.8222
0.0332
0.9258
0.7327
0.0486

*
ns
ns
*
ns
ns
*

DMSO vs.
Unstimulated
DMSO vs. Len 10
DMSO vs. Pom 10
DMSO vs. JQ1 10
DMSO vs. dBET1 0.1
DMSO vs. dBET1 1
DMSO vs. dBET1 10

0.0001
0.0042
0.0166
0.0001
0.0001
0.0001
0.0001

****
**
*
****
****
****
****

0.0001
0.8548
0.8545
0.0007
0.1391
0.9999
0.0003

***
ns
ns
***
ns
ns
***

Comparisons

Division Index

CD98 MFI

Relative Viability to
DMSO (%)

DMSO vs.
0.0001
****
0.0008
Unstimulated
DMSO vs. Len 10
0.0403
*
0.0888
DMSO vs. Pom 10
0.0058
**
0.5164
DMSO vs. JQ1 10
0.0001
****
0.0014
DMSO vs. dBET1 0.1
0.0009
***
0.4613
DMSO vs. dBET1 1
0.0001
****
0.6999
DMSO vs. dBET1 10
0.0001
****
0.0201
P value: * < 0.05, ** < 0.01, *** < 0.001, **** < 0.0001
Note: One-way ANOVA test was performed
Division Index

Treatment
Unstimulated

P value
0.155588597

DMSO
Len 10
Pom 10
JQ1 10
dBET1 0.1
dBET1 1
dBET1 10

0.504634139
0.199850179
0.556480278
0.38380327
0.005508063
0.001725291
0.355268196

CD98 MFI

Summary

**
**

P value
0.05084322
0.892919422
0.330034149
0.340153344
0.175397332
0.0013032
0.011696605
0.567427617

Summary

**
*

***
ns
ns
**
ns
ns
*

Relative Viability to DMSO
(%)
Summar
P value
y
0.83166901
>0.99999999
9
0.015520559
*
0.024144854
*
0.041173393
*
0.000683123
***
0.000215894
***
0.019352985
*

P value: * < 0.05, ** < 0.01, *** < 0.001, **** < 0.0001
Note: Holm-Sidak multiple comparison t-test was performed comparing Crbn+/+ to
Crbn-/- T cells
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A

B

Figure 19. Drug Treatment of human and mouse multiple myeloma cell lines. (A)
BaF/3, mouse B cell lymphoma, and BaF/3 with full length human CRBN (hCRBN)
overpression were treated with Pom, CC-122 (Ava) or vehicle control DMSO. Ikaros and
vinculin (loading control) expression levels were assessed via western blot analysis. (B)
MM1.S and 5TGM1 cells were treated with increasing concentrations of dBET1 for 24
hours. Protein expression levels of BRD4, c-Myc, CRBN, β-actin were determined by
western blot.
Discussion
CRBN was first identified in mild autosomal recessive non-syndromic intellectual
disability (ID) [122], but has poorly defined physiological functions. Interactions have been
reported with the AMP-activated protein kinase (AMPK) α1 subunit [58], TAK1/TRAF6
[123], and CD147/MCT1 complex [61] where CRBN plays ubiquitin-independent roles in
pathway regulation. The mechanistic underpinnings for induced limb deformities in
chickens and zebrafish, but not in mice, appears dependent on sequence differences in
mouse CRBN [31], which brings into question whether these differences in CRBN render
it functionally inactive. Although reference CRBN sequences for nearly all examined
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primates possess Val388, according to the Exome Aggregation Consortium (ExAC), the
Ile391 variant occurs in humans at a frequency of 0.005% (rs756414303). Our data shows
that mutating Val388 to Ile (V388I) does not alter binding affinity to the immunomodulatory
compounds suggesting that the contact between the immunomodulatory drug and the
CRBN-TBD is maintained and potentially functionally active. When bound to
immunomodulatory drugs (Len, Pom, and CC-122), CRBN induces the destruction of
three substrates Ikaros, Aiolos, and CK1α [35] via a V388 interaction [14]. In T cells, the
IKZF-family transcription factors repress IL2 so that ubiquitin-mediated destruction may
be responsible for promoting T cell activation [33, 35]. Our data solidifies the mechanistic
involvement of CRBN Ile391 in drug resistance in in mouse cell lines, as suggested
previously by overexpression of hCRBN with V388, but not I391 in Ba/F3 cells was
sufficient to restore Ikaros protein destruction [31, 35].
As expected, using dBET1, there was no Ikaros degradation in mouse T-cells or
mouse myeloma cell lines. However, we found that dBET1, impressively reduced the
expression of BRD4 in both human and mouse cells. Therefore, proximity-associated
ubiquitin conjugating functions of mouse and human CRBN are confirmed using dBET1.
Crbn-/- T-cells demonstrated that dBET1 functions through a CRBN-TBD dependent
process. Competition with Pom further suggests that the TBD of human and mouse
CRBN have similar binding modes for immunomodulatory compounds suggesting that
there is both structural and functional conservation. Thus, the endogenous E3-ubiquitin
ligase activity and assembly of the CRBN-DDB1-CUL4A containing complex is
fundamentally conserved across the vertebrate lineage, including the mouse, and likely
other species, expressing Ile391. Moreover, other sequence variants present in mouse
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CRBN, including difference in the N-terminus, fail to impact its substrate recruiting
functions when targeting BRD4. This observation along with the high degree of CRBN
conservation indicates that selective pressure has maintained the overall structure and
function in CRBN for over 400 million years.
Using ITC and fluorescence-based binding assays, we establish that the
dissociation constants of thalidomide and other immunomodulatory compounds to mouse
CRBN are similar to human CRBN, which is consistent with analysis of the crystal
structure of human CRBN-DDB1 in complex with Len [13, 112]. As suggested previously
[112], the W380A mutant completely abolished binding and confirms that this is one of
the key residues of the binding pocket. Trp380 also appears to work synergistically with
other binding pocket residues (Trp386, Trp400 and Phe402) for ligand interaction. The
KD values of immunomodulatory compounds in complex with the human TBD (aa 319425) are in the µM range similar to those of C. elegans and Magnetospirillum
gryphiswaldense [124]. Based on the conserved CRBN structure, we synthesized Nmethyl derivatives of Len and dBET1 which proved useful in assessing the functional
contribution of this ligand interaction in vivo in mouse and human cells.
Here, we show an interesting reliance of the rigid TBD binding pocket on Nterminal sequences and plays a previously unappreciated role in optimal ligand binding.
A conformational change in full-length CRBN-DDB1 may occur upon ligand binding as
shown by the difference in their ∆H and ∆S values (Figure 13). Notably, the CRBN-DDB1
complex and CRBN-TBD show marked difference in Len binding affinity by ITC. In fact,
a closer inspection of the crystal structure of full-length CRBN in complex with Len
illustrates that a disordered loop in the TBD consisting of residues Asn351, Pro352, and

55

His353 stabilizes the interaction of Len. Asn351 forms a hydrogen bond to carbonyl
oxygen of Len’s isoindolinone ring and both Pro352 and His353 form hydrophobic
interactions with the aromatic system of the immunomodulatory drug (Figure 13E).
Importantly, the mouse TBD crystal structure shows poor electron density in this loop
structure suggesting it is a highly unstructured and dynamic region. Alternatively, other
residues outside the TBD could have stabilized this loop. The side chain of Gln100, which
is located in the LON domain of CRBN, forms a weak hydrogen bond interaction to the
ɛ2NH group of His378. This in turn positions the δ1NH of His378 as a hydrogen donor to
the immunomodulatory drugs. These important structural domains should be further
investigated in immunomodulatory drug discovery.
Collectively, our results suggest that PROTAC molecules and possibly other
CRBN-bound compounds may adopt an active conformation that is susceptible to CRBNdirected, cullin-RING E3 ligase-mediated polyubiquitination in mouse cells. PROTAC
molecules are designed to harness the CRBN-binding properties of IMiD®s and initiate
the degradation of oncogenic targets. Several IMiD®-based BET targeting PROTACs
such as dBET-1, ARV-825 and BETd-260have been developed to potently that degrade
BRD4 [52, 125, 126] Intracellular protein degradation of FK506 binding protein (FKBP12)
was also achieved by a conjugate of thalidomide [51, 127], but originally, methionine
aminopeptidase-2 (MetAP-2)[46], estradiol (E2) and dihydrotestosterone (DHT) were
degraded by engaging the Skp1-Cullin-F-box (SCF) ubiquitin ligase through a 10 amino
acid phosphopeptide derived from IκBα [50, 128]. PROTAC with specificity for the von
Hippel-Lindau (VHL) ubiquitin ligase E3 have also been developed [129, 130]. Recently,
BRD4 and ERK1/2 degradation was induced by the interaction of two smaller precursors
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molecules that undergo intracellular self-assembly which improves solubility and cellular
permeability of thalidomide-containing PROTAC inhibitors [131]. Importantly, our studies
establish that mouse platforms can indeed be used for preclinical development of dBET1,
and possibly other PROTAC-based chemical degraders that are designed to re-direct
CRBN’s substrate binding function toward specified endogenous proteins [46, 50, 51,
125, 131, 132]. Toxicology and functional testing of such agents in rodents and mouse
tumor models may yield important preclinical information. CRBN interacts intracellularly
with calcium-activated potassium channels and the metabolic sensor adenosine
monophosphate-activated protein kinase (AMPK), which in the latter, suppresses its
activation and its downstream target mammalian target of rapamycin (mTOR) [58, 133,
134]. Collectively, this data suggests that there may be multiple endogenous substrates
of CRBN and that the immunomodulatory drugs may influence its physiological function.
One study in particular proposes a ubiquitin-independent physiological role CRBN as a
chaperon stabilizing the CD147-MCT1 complex [135]. In this study, researchers show the
CD147-MCT1 complex is vital for the regulation of cellular metabolism and expression of
fibroblast growth factor 8, which is the transcription factor reported to mediate
thalidomide-associated teratogenicity in zebrafish and chickens [28]. Furthermore,
through elegantly designed experiments, researchers show that thalidomide treatment
destabilizes the CD147-MCT1 complex and that morpholino-induced loss of CD147
suppress limb development similar to drug treatment [135].
Collectively, these studies provide insight into aspects of CRBN biology relevant
for the preclinical development of PROTAC compounds in humans. Moreover, we
highlight the potential disadvantages of using CRBN-targeting PROTAC compounds as
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they all may harbor teratogenic potential. Using new agents, it may be possible to
understand fundamental roles for CRBN and avoid its proteasome or non-proteasomerelated protein targets that are associated with fetal development.

Experimental Procedures
Animals and cell lines
Germline Crbn deficient mice (Crbn-/-) were described previously [122] and gene
deletion was confirmed using wild-type and Crbn-KO-specific primers. C57BL/6 (Crbn+/+)
mice were purchased from Jackson Laboratory (Farmington, CT) and were then bred to
Crbn-/- mice. Crbn+/+ and Crbn-/- littermates from Crbn+/- intercrosses were used for our
studies. Mice were maintained and bred at the H. Lee Moffitt Cancer Center and Research
Institute under a protocol approved by the Institutional Animal Care and Use Committee
(IACUC). The human multiple myeloma cells including U266, H929, MM1.S, and the
mouse multiple myeloma cell line 5TGM1, were generous gifts of Drs. Ken Shain and
Connor Lynch (Moffitt Cancer Center, Tampa, FL). All cell lines were mycoplasma free
and sequence verified.

T-cell isolation, activation and drug treatments
Human polyclonal CD3+ T cells or CD8+ T cells were isolated from peripheral
blood donations to the Southwest Florida Blood Services. Since personal identifying
information is unavailable, the research was deemed non-human research. Human and
mouse T cells were isolated from Crbn+/+ and Crbn-/- splenocytes by immunomagnetic
negative selection (Miltenyi Biotec, San Diego, CA) and >95% purity was confirmed by
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flow cytometry. For drug treatment experiments, 12-well flat bottom plates were coated
with 5 µg/mL anti-CD3ε (clone# HIT3a, eBioscience or clone# 145-2C11) in 1x PBS at
37ºC for 60 min. Cells were plated at 2-4x106 cells per well with anti-CD28 (clone#
CD28.2, eBioscience or clone# 37.51, eBioscience). Following 12 h of activation, the cells
were treated with DMSO (0.1%, Sigma-Aldrich, MO), Len (10 µM) (Celgene, NJ), Pom
(Sigma-Aldrich), and JQ1 (doses indicated) (Cat# SML0974, Sigma-Aldrich). N-methylLen, dBET1, and N-methyl-dBET1 were all synthesized at Moffitt Cancer Center
(described in supplementary material) and used at the doses indicated. After 12 hrs of
drug treatment, cells were harvested, and protein levels were examined by western blot
analysis. For proliferation experiments using mouse T cells, 0.1-10 µg/mL anti-CD3ε
(clone# 145-2C11, eBioscience) was used with cells plated with and without anti-CD28
for 72 h. Cytokine expression was determined using supernatants that were harvested at
24 or 48 h and quantified from standard curves by enzyme-linked immunosorbent assay
(ELISA) according to the manufacturer’s protocol. Kits were purchased from eBioscience
(IL-2) and R&D Systems for other cytokines. For functional analysis of T cells treated with
JQ1, murine CD3+ T cells from Crbn+/+ and Crbn-/- splenocytes and human T cells were
labeled with 5-10 µM CellTrace Violet (C34557, ThermoFisher) and activated with 5
µg/mL anti-CD3ε and 1µg/mL anti-CD28 for 72 h in round-bottom 96-well plates. Cells
were stained with CD98-PE (clone# RL388, Biolegend), 7-AAD (BD Pharmingen) and
Zombie NIR™ Fixable Viability Kit (Cat # 423105, Biolegend) and analyzed on a BD
LSRII.
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qRT-PCR
Isolated T cells from Crbn+/+ and Crbn-/- mice were lysed, homogenized
(Qiashredder, Qiagen), and total RNA extracted (RNeasy, Qiagen) according to
manufacturer protocol. Complementary DNA was generated from isolated RNA (iScript
cDNA synthesis Kit, Bio-Rad). RNA expression was analyzed by quantitative real timepolymerase chain reaction (qRT-PCR) using Taqman Universal PCR Master Mix for
Taqman probes (Thermo Fischer Scientific) against (cDNA) c-Myc (Mm00487804_m1)
and (cDNA) β2M (Mm00437762_m1). Samples were run on an Applied Biosystems 7900
HT and Sequence Detection Systems software.

Treatment of multiple myeloma cells
Mouse and human multiple myeloma cell lines were plated at 2-4x106 cells per well
in a 12-well plate with various concentrations of Len and Pom. To confirm target
degradation, the cells were treated with varying concentrations of dBET1 (0, 0.01, 0.1, 1,
and 10 µM) for 12-24 h. Following drug treatment, protein levels were examined by
western blot analysis relative to vinculin or β-actin to normalize for protein expression.
For proliferation studies, 1-2x104 cells per well were seeded in a 96-well plate and were
treated with using cell-counting-8 kit (CCK8) (Dojindo, Rockville, MD) according to
manufacturer’s protocol.

General chemistry information
All reagents were purchased from commercial suppliers and used without further
purification (except where mentioned otherwise). 1H NMR spectra were recorded on an
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Agilent-Varian Mercury 400 MHz spectrometer with DMSO-d6 as the solvent. All coupling
constants are measured in Hertz, and the chemical shifts (δH) are quoted in parts per
million relative to TMS (δ 0), which was used as the internal standard. High-resolution
mass spectroscopy was carried out on an Agilent 6210 LC−MS (ESI-TOF) system. HPLC
analysis was performed using a JASCO HPLC system equipped with a PU-2089 Plus
quaternary gradient pump and a UV-2075 Plus UV−Vis detector, using an Alltech
Kromasil C-18 column (150 × 4.6 mm, 5 μm) and an Agilent Eclipse XDB-C18 column
(150 × 4.6 mm, 5 μm). The purities of the final compounds used for the biochemical and
functional studies were >95% as measured by HPLC. Melting points were recorded on
an Optimelt automated melting point system (Stanford Research Systems). Thin-layer
chromatography was performed using silica gel 60 F254 plates (Fisher Scientific), with
observation under UV when necessary. Anhydrous dimethylformamide was used as
purchased from Sigma Aldrich. Burdick and Jackson HPLC-grade solvents were
purchased from VWR for HPLC, HPLC-MS and high-resolution mass analysis. dBET1
(HPLC purity 98%) was prepared from JQ1 as described [51]. Detailed information about
the synthesis of N-methyl-Len, and N-methyl-dBET1 synthesis are provided in the
supplementary material.
Cloning, protein expression and purification
The full-length hCRBN protein (isoform 1) in complex with the DNA-damage
binding protein (DDB1) was a generous gift from Celgene Corporation (San Diego, CA).
The gene coding for the human TBD (aa 319-425) was synthesized and subcloned into
the BamHI-NotI restriction sites of the pGEX-6P-1 vector by GeneArt® Gene Synthesis.
The gene was engineered with silent mutations that utilize the favored E. coli codons.
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TBD E377V, V388I, H378A and W380A mutations were performed using polymerase
chain reaction. Details of primer sequences are provided in supplemental material.
Mutations were confirmed by sequencing. The recombinant DNA plasmids were
transformed into E. coli Rosetta™ 2(DE3)pLysS competent cells (EMD Millipore, Billerica,
MA) for subsequent protein expression. The GST-tagged TBD proteins linked with
PreScission protease proteolytic site were expressed and purified as follows: A single
colony of freshly transformed cells was cultured at 37 °C for 16 h in 5 mL of Luria-Bertani
(LB; Thermo Fisher Scientific) medium containing 100 µg/mL of ampicillin (Sigma-Aldrich)
and 34 μg/mL of chloramphenicol (Sigma-Aldrich). 1 mL of the culture was then used to
inoculate 25 mL of Terrific Broth-phosphate medium (TB; Thermo Fisher Scientific) with
100 µg/mL ampicillin at 37 °C for 16 h. The culture was then transferred to 1.5 L of TB
medium supplemented with 50 µM ZnCl2 (Sigma-Aldrich). The resultant culture was
incubated with continuous shaking at 250 rpm to an OD600 of 0.70 and then induced with
isopropyl-β-D-1-thiogalactopyranoside (IPTG; 0.5 mM final concentration; Thermo Fisher
Scientific) at 16 °C for 20 h prior to harvesting by centrifugation at 6000 rpm for 30 min.
The cells were lysed by homogenization in 50 mM Tris (pH 8.0; Sigma-Aldrich), 500 mM
NaCl (Thermo Fisher Scientific), 1 mM TCEP (Sigma-Aldrich), 0.1% Triton X-100 (SigmaAldrich), 10 µM ZnCl2 (Acros Organics, Thermo Fisher Scientific) and protease inhibitor
cocktail (Roche). The protein was then purified by affinity chromatography on an AKTA
Explorer or AKTA Purifier (GE Healthcare Life Sciences) using a glutathione-Sepharose
matrix (GE Healthcare Life Sciences, Pittsburgh, PA) pre-equilibrated with 50 mM Tris
(pH 8.0), 500 mM NaCl, 1 mM TCEP, and 10 µM ZnCl2, and eluted with the same buffer
with the addition of 10 mM reduced glutathione (Sigma-Aldrich). Purity of the protein in
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the different fractions was determined by SDS-PAGE and the best fractions were pooled.
GST was cleaved from the pooled GST-TBD fractions by digestion with PreScission
protease at 4 °C for 4 h. GST was removed from the resultant digest by a second round
of GST affinity chromatography. Proteins were further purified by size-exclusion
chromatography in a Superdex 75 column (GE Healthcare Life Sciences). Fractions with
>90% purity were pooled, concentrated by ultrafiltration (10K Amicon tubes, EMD
Millipore) and stored at -80 °C.

Isothermal titration calorimetry (ITC)
The binding of CRBN-DDB1 complex and CRBN-TBD wild-type and mutant
variants to immunomodulatory compounds was analyzed with MicroCal iTC200 titration
calorimeter (Malvern, Westborough, MA). The compound phthalimide was used as the
negative control. The proteins were re-buffered into binding buffer (50 mM HEPES (pH
7.5, Sigma-Aldrich), 200 mM NaCl, 0.1 mM TCEP and 0.6% DMSO). For the titrations of
the protein constructs, a total of 19 aliquots (2.05 μl each) of the respective compounds
(~600 μM) were injected into 200 μl of the protein solutions (40 μM) at 25°C. The ITC cell
mixture was constantly stirred at 1000 rpm and recorded for 160 s between injections at
low feedback. The corrected heat values were fitted using a nonlinear least square curvefitting algorithm (Microcal Origin 7.0, OriginLab, Northampton, MA) to obtain binding
constants (KD) and values for n (number of binding sites), ΔH (enthalpy) and ΔS (entropy).
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Intrinsic tryptophan fluorescence assay
Binding of compounds to wild-type and mutant TBD was monitored by
fluorescence spectroscopy, using an adapted previously published method [107, 124]. All
chemicals used in this assay were purchased from Sigma-Aldrich unless otherwise
stated. In this assay, changes in emission spectra are induced by interactions of these
compounds with the three Trp residues (Trp380, Trp386 and Trp400) in the binding site
[13, 112]. TBD proteins (final concentration, 10 µM) were incubated with varying final
concentrations (0-750 µM) of compounds in assay buffer (50 mM Tris, pH 7.5, 200 mM
NaCl, 0.1% Pluronic-F127, and 1 mM TCEP) to a final volume of 40 µL in a black 96-well
half area plate (Corning, Corning, NY). A 0.5% final DMSO concentration was used in
each well. Samples were excited at 280 nm and fluorescence emission intensities were
measured at 340 nm using Wallac Envision 2102 multilabel plate reader (Perkin Elmer,
Waltham, MA). All measurements were done in triplicate and corrected for inner filter
effect to subtract for ligand-associated fluorescence, as described [136]. The magnitude
of fluorescence difference (1-F/F0) was measured where F is the fluorescence emission
at a given concentration of ligand; F0 is the intrinsic fluorescence intensity of 10 µM of
TBD protein alone. Graph plotting and curve fitting to obtain apparent dissociation
constant (KD) values were calculated by fitting the relative change in intrinsic fluorescence
at 340 nm (1-F/F0) versus ligand concentration to a nonlinear regression with one-site
binding hyperbola with GraphPad Prism Software (GraphPad Software, La Jolla, CA).

Theoretical Calculations
The preparation of the protein systems for human cereblon (hCRBN, PDB
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4TZ4[112], murine cereblon (mCRBN, PDB 4TZC and 4TZU)[112] and galline cereblon
(gCRBN, PDB 4CI1, 4CI2, and 4CI3)[13] were done using the Schrodinger software suite
(Maestro, version 9.7, Schrödinger, LLC, New York, NY, 2014). Protein structure
coordinates were downloaded from the Protein Data Bank (PDB) [137, 138] and prepared
with the Protein Preparation Wizard (PrepWizard) in Maestro (Schrödinger Suite 2014-1
Protein Preparation Wizard; Epik version 2.7, Schrödinger, LLC, New York, NY, 2013;
Impact version 6.2, Schrödinger, LLC, New York, NY, 2014; Prime version 3.5,
Schrödinger, LLC, New York, NY, 2014)[139]. Final system equilibration was determined
by the observation of asymptotic behavior of the potential energy, RMSD, and Rg profiles
and visual inspection of trajectories guided by RMSF profiles (supplementary material
provides additional detailed settings). MD simulations were performed with the Desmond
MD program with additional details provided in Supplementary Materials and Methods
(Desmond Molecular Dynamics System, version 3). After equilibration was determined, a
hierarchical average linkage clustering method based on RMSD was utilized to determine
an average representative structure for each equilibrated system. The program PROPKA
was then implemented again on the equilibrated structures to test consistency of side
chain protonation states at7.4 pH.

Detailed chemical methods
Synthesis of tert-Butyl (2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)carbamate
(1):
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Lenalidomide (259 mg, 1 mmol) and Boc2O (218 mg, 1.1 mmol) were mixed in THF (1
mL) in a sealed tube and stirred at 60 °C overnight. The next day, Boc2O (110 mg, 0.5
equiv.), THF (1 mL), and DMF (0.5 mL) were added and the solution was further stirred
at 120 °C overnight. Water (20 mL) was added and the mixture was sonicated. The
precipitate was filtered, washed with water (10 mL), and dried. The resulting solid was
triturated using EtOH/EtOAc/hexanes and filtered to give the desired product as an offwhite solid (258 mg, 72%). Mp: 196–198 °C. HPLC–MS (ESI+): m/z 741.3 ((100%,
2M+Na)+), 719.4 ((40%, 2M+H)+), 360.2 ((90%, M+H)+). 1H NMR (400 MHz, DMSO-d6):
δ 11.00 (s, 1H), 9.21 (s, 1H), 7.74 (dd, J = 6.8, 1.7 Hz, 1H), 7.49–7.39 (m, 2H), 5.10 (dd,
J = 13.3, 4.7 Hz, 1H), 4.41 (d, J = 17.6 Hz, 1H), 4.32 (d, J = 17.6 Hz, 1H), 2.95–2.83 (m,
1H), 2.64–2.54 (m, 1H), 2.40–2.26 (m, 1H), 2.05–1.95 (m, 1H), 1.46 (s, 9H). Compound
1 was reported previously [51].
tert-Butyl (2-(1-methyl-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)carbamate (2):
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To a mixture of 1 (100 mg, 0.278 mmol) and K2CO3 (38 mg, 0.278 mmol) in DMF (0.8
mL) was added methyl iodide (0.017 mL, 0.278 mmol) dropwise at room temperature
under Argon. The mixture was stirred overnight. Water (10 mL) was added and extracted
with EtOAc (2 × 20 mL). The combined organic layers were dried (Na2SO4), filtered, and
concentrated under reduced pressure. The resulting yellow oil was purified by flash
chromatography (SiO2) eluting with hexanes in EtOAc (80% to 100%) to provide the title
compound as a white solid (40.37 mg, 39%). Mp: 192 °C (dec). HPLC–MS (ESI+): m/z
741.3 ((100%, 2M+Na)+), 719.4 ((40%, 2M+H)+), 360.2 ((90%, M+H)+). 1H NMR (400
MHz, DMSO-d6): δ 9.20 (s, 1H), 7.73 (dd, J = 6.5, 2.3 Hz, 1H), 7.49–7.41 (m, 2H), 5.16
(dd, J = 13.4, 5.1 Hz, 1H), 4.42 (d, J = 17.6 Hz, 1H), 4.30 (d, J = 17.6 Hz, 1H), 3.02–2.90
(m, 1H), 2.99 (s, 3H), 2.80–2.71 (m, 1H), 2.40–2.27 (m, 1H), 2.07–1.97 (m, 1H), 1.46 (s,
9H).
3-(4-Amino-1-oxoisoindolin-2-yl)-1-methylpiperidine-2,6-dione

(3

or

N1-methyl-

lenalidomide): 2 (35 mg, 0.093 mmol) was stirred in 4 M HCl in dioxane (0.5 mL) for 3.5
h at room temperature. The white suspension was concentrated under reduced pressure
and the resulting solid was triturated in DCM/hexanes, washed with EtOAc and hexanes
(10 mL each), and dried to provide the title compound as light yellow flakes (21.81 mg,
75%). Mp: 207 °C (dec). HPLC: 99% (tR = 11.6 min, 10% MeOH, 90% water (with 0.1%
TFA), 20 min). 1H NMR (400 MHz, DMSO-d6): δ 7.29 (t, J = 7.5 Hz, 1H), 7.11 (d, J = 7.5
Hz, 1H), 6.99 (d, J = 7.5 Hz, 1H), 5.17 (dd, J = 13.4, 4.7 Hz, 1H), 5.20–4.80 (br s, 2H,
disappeared on D2O shake), 4.28 (d, J = 17.0 Hz, 1H), 4.17 (d, J = 17.0 Hz, 1H), 3.05–
2.91 (m, 1H), 2.99 (s, 3H), 2.80–2.70 (m, 1H), 2.39–2.25 (m, 1H), 2.08–1.97 (m, 1H).
HPLC–MS (ESI+): m/z 569.2 ((30%, 2M+Na)+), 274.2 (
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(100%, M+H)+). LC–MS (ESI+): 569.2 (40%, (2M+Na)+), 296.1 (100%, (M+Na)+). HRMS
(ESI+): m/z calcd for C14H15N3O3 (M+H)+ 274.1186, found 274.1176.

2-((S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno(3,2-f)(1,2,4)triazolo(4,3a)(1,4)diazepin-6-yl)-N-(4-(2-((2-(1-methyl-2,6-dioxopiperidin-3-yl)-1,3dioxoisoindolin-4-yl)oxy)acetamido)-butyl)acetamide

(Me-dBET1):

This

was

prepared from N-Boc amino glutarimide as a white solid. HPLC: 99% (tR = 24.7 min,
gradient 5-95%, MeOH-water (with 0.1% TFA), 30 min). 1H NMR (400 MHz, Methanol-d4)
δ 7.82 (dd, J = 8.4, 7.4, Hz, 1H),7.53 (dd, J = 7.2, 0.4 Hz, 1H), 7.47–7.38 (m, 5H), 5.14
(dt, J = 12.9, 5.1 Hz, 1H), 4.78 (s, 2H), 4.62 (ddd, J = 9.0, 5.2, 0.7 Hz, 1H), 3.44–3.34 (m,
3H), 3.30–3.22 (m, 3H), 3.11 (2 xs, 3H), 2.86–2.82 (m, 2H), 2.73–2.62 (m, 4H), 2.43 (2 x
d J = 0.9 Hz, 3H), 2.12–2.03 (m, 1H), 1.72–1.69 (m, 3H), 1.67–1.59 (m, 4H); HPLC–MS
(ESI+): m/z 821.2 ((100%, M+Na)+), 799.3 ((70%, M+H)+); HRMS (ESI+): m/z calcd for
C39H39ClN8O7S (M)+ 798.2345, found 798.2368.

Detailed protein production of wild-type and mutant CRBN.
The primers used are:
1.

5'-CCAGTCTGTGTTGTAAACAGAGCCAAGAAACC-3' and
5'-GGTTTCTTGGCTCTGTTTACAACACAGACTGG-3’;

2.

5'- GGTTATGCATGGACCATCGCACAGTGTAAAATTTGTGC-3' and
5'-GCACAAATTTTACACTGTGCGATGGTCCATGCATAAC-3',
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3.

5'-CGTCCGAGCACCGAAGCAAGCTGGTTTCCGGGTTATGC-3' and
5'- GCATAACCCGGA AACCAGCTTGCTTCGGTGCTCGGACG-3';

4.

5'-CGAGCACCGAACATAGCGCGTTTCCGGGTTATGCATGG-3' and
5'-CCATGCATAACCCGGAAACGCGCTATGTTCGGTGCTCG-3',
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CHAPTER THREE
CEREBLON E3 UBIQUITIN LIGASE RECEPTOR CONTROL OF HEMATOPOIESIS
Introduction
The hematopoietic system consists of heterogenous populations that undergo
continuous

processes

leading

to

the

hierarchical

differentiation

of

immature

multifunctional blood cell lineages that originate from a primordial hematopoietic stem cell
population (HSC) with the capacity for multipotent differentiation. During embryonic
development, HSCs emerge from the hemogenic endothelium in the dorsal aorta-gonad
mesonephros (AGM) region [73] at gestational day 10 (E10) and subsequently colonize
the fetal liver. Thereafter during adult hematopoiesis, HSCs primarily reside in complex
bone marrow niches where both internal and external factors control the differentiation of
multipotent and committed progenitors into defined mature blood cell populations
including erythrocytes, megakaryocytes, platelets, lymphocytes, monocytes, and
granulocytes. While mature blood cells are predominantly short lived, the most rare and
primitive stem cells, long-term HSCs (LT-HSCs) (Lin- Sca-1+ c-Kit+ CD150+ CD48- CD34CD135-) in particular, maintain extensive self-renewal capabilities throughout life.
Mature LT-HSCs reside in specified bone marrow niches, predominantly the
endosteal and sinusoidal niches, where they maintain long-term quiescence with brief
intervals of self-renew. Control of HSC cell fate consists of an intricate network of cellintrinsic and extrinsic factors (listed in Table 9) [140]. Although studies in recent decades
have expanded our knowledge of HSC maintenance in adult bone marrow and during
fetal development, knowledge gaps represent critical barriers for the success of
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hematopoietic stem cell transplantation, human germline gene editing, and therapy for
benign and malignant hematopoietic diseases.
Table 9. Cell intrinsic and extrinsic regulators of HSC quiescence[71]
Cell Intrinsic
Category
Cell cycle

Transcription

Other

Gene
p21
p27
p18
p57
Rb/p107/p130
CyclinD1/D2/D3
Cdk4/6
JunB
Pbx1
FoxO1/3/4
FoxO3a
Nurr1
Sc1
P53
Necdin
Egr1
ELF4
AML1/Runx1
Stat5
Fbw7
Lkb1
Tsc1-mTOR
Cited2
Txnip
Atm
Mi-2β
Paf
Ott1
G0S2
Akt1/2
Lnk

Cell Extrinsic
Control
Of
Quiescence
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
-

Ligand

Receptor

Effect on
Quiescence

Ang-1

Tie2

+

THPO

Mpl

+

Wnt

Frizzled

+

TGFβ

TGFBR

+ only after
cytoablation

IFNγ

IFNGR

-

CXCL12

CXCR4

+

OPN
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+

Hh

Patched

-

SCF

c-kit

+

IMiD®s are highly efficacious drugs in several malignancies of hematopoietic
origin including multiple myeloma (a plasma cell disease), mature B cell malignancies
such as chronic lymphocytic leukemia (CLL) and non-Hodgkin’s leukemia (NHL) as well
as myelodysplastic syndrome (MDS) harboring a chromosome 5q deletion (del5qMDS).
All of these are largely incurable diseases that arise from self-renewing leukemia stem
cell population. Cereblon, the sole molecular target of IMiD®s, may have an unidentified
contribution to HSC regulation given their ability to target stem cells and promote
differentiation. While CRBN has not been characterized in the hematopoietic stem cell
compartment, it regulates the Slo alpha subunit of the BK(Ca2+) ion channel that is
involved in neuronal excitation, and in other cell types CRBN appears to control
metabolism, by directing degradation of glutamine synthetase (GS) via interactions with
acetylated lysines of GS that are triggered by high intracellular glutamine concentrations,
and by CRBN-directed regulation of AMP-activated protein kinase (AMPK), a regulator of
energy homeostasis. Finally, CRBN binds to the CD147-SLC16A1 (MCT1) lactate
transporter complex in multiple myeloma cells. When treated with IMiD®s, patients with
a somatic mutation in del(5q) MDS, a therapeutic response is associated with CD34+ stem
and progenitor cell ablation with parallel expansion of circulating lymphocytes and early
erythroid precursors[141]. Interestingly, hematopoietic stem and progenitor cell (HSPC)
defects in drug-treated del(5q) MDS patient’s bone marrow are quenched while
erythropoiesis and HSPC differentiation improve [141].
To address more fully the role that CRBN plays in HSCs regulation, we combined
both in vitro and in vivo assays to study murine CRBN-deficient HSCs. We show that
germline depletion of CRBN results in a significant reduction in HSC numbers yet an
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expansion of lymphoid and myeloid cells in the peripheral blood. Despite their reduced
numbers, CRBN-depleted HSCs have extensive self-renewal capacity following serial
bone marrow transplantation, however, do not possess a fitness advantage over wildtype CRBN-expressing (Crbn+/+) HSCs in competitive transplantation. Collectively, our
results demonstrate that CRBN plays a previously undefined regulatory role in HSC
maintenance by controlling adhesion during adult and fetal hematopoiesis.

Results:
CRBN expression in adult hematopoietic stem and progenitor cells
Because of the birth defects induced by thalidomide and its derivatives known
collectively as “immunomodulatory drugs” in humans, chicken and zebrafish, we first
characterized gross limb and organogenesis in CRBN germline deficient mice and found
no detectable malformations at birth or through maturation (Figure 20A). Moreover, Crbn/-

mice had no obvious organ defects at necropsy although a significant reduction in body

weight, in males and females, was observed at 3 months and in aged mice (Figure 20B).
The reduction in body weight was pronounced at 13 months where the age-associated
weight gain observed in Crbn+/+ (37.925g ± 3.88g) mice was significantly reduced in Crbn/-

(33.65g ± 2.93g, p=0.02) littermates (Figure 20B), which is consistent with previous

reports of a role for CRBN in controlling diet-induced obesity[142].
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Figure 20. CRBN deletion does not lead to gross abnormalities or birth defects.
Three-month old and eighteen-month old Crbn-/- and Crbn+/+ littermates were assessed
for normal limb formation, weight and Crbn mRNA expression in hematopoietic lineages.
(A) Crbn-/- mice have normal limb development. (B) Twelve-week-old male and female
Crbn-/- and their Crbn+/+ littermates (n=22-25 per genotype) were weighed. Ten to thirteenmonth old males Crbn-/-(n=8) and their Crbn+/+(n=8) littermates were weighed. (C) Gating
strategy to identify the hematopoietic lineages, Lin-, LSK, LT-HSC, ST-HSC, SLAM HSC,
MPP1, MPP2, MPP3, MPP4 populations using combination of cell surface markers
(lineage cocktail, c-Kit, Sca-1, CD34, CD135, CD48 and CD150). (D) Purified Lin+, LSK,
LT-HSC, ST-HSC & MPP were FACs sorted from bone marrow isolated from 2 tibias, 2
femurs and 2 iliac crest per mouse from Crbn+/+ (n=7) and Crbn-/- (n=8). mRNA expression
of Crbn normalized to Beta-2 microglobulin (β2M) and relative to Lin+ Crbn+/+ was
confirmed in all lineages. Multiple Student’s t-test per population was performed and
significance achieved at *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001
Interestingly, Crbn mRNA levels in lineage positive (Lin+), LSK (Lin-Sca-1+c-Kit+),
LT-HSC (Lin-Sca-1+c-Kit+CD48-CD150+), ST-HSC (Lin-Sca-1+c-Kit+CD48-CD150-), and
MPP(Lin-Sca-1+c-Kit+CD48+CD150-), populations from femoral and tibial bone marrow of
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Crbn-/- (n=8) and Crbn+/+ (n=7) littermates (Figure 20C) showed that lineage positive cells
(Lin+) have the highest expression of CRBN while the pluripotent LSK population has the
lowest expression and, as expected, no Crbn mRNA detectable in Crbn-/- bone marrow
cells. Compared to Lin+ cells, CRBN expression levels was lower in LT-HSCs and this
difference was even more pronounced in the ST-HSC and MPP populations (Figure 20D).
Hence, CRBN’s expression pattern may reflect a cell-specific dependency on its function.

CRBN regulates the frequency of adult hematopoietic stem and non-committed
progenitor cells
To further address the role of CRBN in HSCs under homeostatic conditions, we
evaluated the frequency of HSPCs in the bone marrow of age- and sex-matched Crbn-/mice and Crbn+/+ littermates. Using flow cytometry and cell counts, the proportion and
absolute number of all stem and non-committed progenitor cells was > 2-fold lower in
Crbn-/- bone marrow (Figure 21B-E) with no notable changes in the precursor populations
including CMP (Lin−Sca-1−c-kit+CD34+FcγRlo), GMP (Lin−Sca-1−c-kit+CD34+FcγRhi), and
MEP (Lin−Sca-1−c-kit+CD34−FcγRlo) (Figure 21F) and a trending decrease in BM
cellularity (Figure 21A). Interestingly, while the frequency of LSK cells in the BM of
Crbn−/− and Crbn+/+ mice were similar, (Figure 21G) their absolute numbers were
reduced (Figure 21D). Crbn-/- LT-HSC had the highest decrease in absolute counts
(Figure 21E, p= 0.00004) and frequency (Figure 21H) over control. Flow cytometric
analysis of caspase 3/7 (activated proteases that mediate programmed cell death)
showed no differences in total apoptosis in Crbn-/- compared to Crbn+/+ WBM cells or
apoptosis frequencies in distinct populations including Lin-, LSKs, MPP, ST-HSC and LT75

HSC (Figure 21I) suggesting that the reduction in HSCs is not coupled to enhanced
caspase activation and associated apoptotic cell death.

Figure 21. CRBN deletion causes a loss in absolute hematopoietic stem and
progenitor counts. Crbn-/- and Crbn+/+ bone marrow (1 tibia and 1 femur) were analyzed
via flow cytometry for frequency and absolute counts (extrapolated from whole bone
marrow counts (WBM)) at 2-3 months (n=4-5/genotype). Absolute counts of WBM (A),
Lin-(B), Lin-c-Kit+(LK) (C), Lin-Sca-1+c-Kit+(LSK), multipotent progenitor (MPP) & shortterm hematopoietic stem cell (ST-HSC) (D) and long-term HSC (LT-HSC) (E) from freshly
isolated bone marrow of Crbn-/- (n=4) and Crbn +/+ mice(n=4). (F) Absolute cell counts of
more committed progenitors, CMP, GMP, MEP populations from mice in (A-E).
Representative scatter plots comparing LSK (G) and LT-HSC (H) frequencies between
Crbn-/- and Crbn+/+. (I) Total apoptosis measured by caspase 3/7 expression in
hematopoietic cells from Crbn-/-(n=5) and Crbn+/+ (n=4) littermates. Multiple Student’s ttest per population was performed and significance achieved at *p<0.05, **p<0.01,
***p<0.001, ****p<0.0001
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Age-related hematopoiesis
Stem and progenitor cells drastically change in both frequency and function with
age[143]. In Crbn+/+ at 3 months LT-HSC, ST-HSC and MPP represent ~7%, 20% and
~70% of LSKs. These frequencies remain relatively consistent at 6 months. However, by
13 months LT-HSC expand at the expense of ST-HSC and MPP population with
frequencies at ~40%, 16% and ~40% (Figure 22A) consistent with literature[143, 144].
Enumeration of primitive LT-HSC frequencies (39.7 ± 10.0%) and absolute numbers
showed an age-dependent accumulation in older Crbn+/+ mice (18 months old, n=3);
whereas, the LT-HSCs demonstrated lower frequencies (17.5 ± 4.7%, p=0.01) and
numbers in Crbn-/- mice (n=4) (Figure 22C,F). LT-HSC decreased numbers in Crbn-/- mice
were accompanied by trending increases in WBM, Lin- and MPP populations that failed
to reach significance but suggest increased differentiation (Figure 22F).
Under homeostasis, HSCs are slow cycling therefore limit the need for metabolic
activity and thus generate low levels of reactive oxygen species (ROS). However, with
aging, ROS levels accumulate which contribute to increased proliferation, senescence,
or apoptosis[145, 146]. ROS levels increased over time in Crbn+/+ LT-HSC (Figure 22B)
but there were no detectable changes in ROS levels between Crbn+/+ and Crbn-/- mice at
18 months (Figure 22D). Interestingly, however Crbn-/- LT-HSC demonstrated a trending
increase in total apoptosis as measured by caspase 3/7 expression (p=0.09) (Figure
22E). Suggesting that while ROS level are similar, sensitivity to ROS-induced cell death
is heightened in Crbn-/- LT-HSC.
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Figure 22. Loss of HSC pool persists in aged Crbn-/-. (A) Stem cell levels and
intracellular reactive oxygen species (ROS) (B) levels were measured via flow cytometric
analysis from Crbn+/+ mice aged 3,6,13 months (n=1). Data represents one out of 3
experiments. (C) Stem cell frequencies from 18-month old Crbn+/+ (n=3) and Crbn-/- (n=4,
only 3 shown) were analyzed and intracellular ROS in LT-HSC was measured (D). (E)
ROS levels in LT-HSC were quantified by geometric mean fluorescent intensities (left)
and total apoptosis in LT-HSC via caspase 3/7 staining (right) from mice in (C). (F)
Absolute cell counts from mice in (C). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001
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CRBN expression is required for normal embryonic HSC development
While all mature blood cells arise from the bone marrow, fetal hematopoiesis in
vertebrates, including mice and humans, initiates from aorta-gonad mesonephros (AGM)
regions and then colonize the fetal liver where colonization, survival and proliferation are
defined by recruitment and localization in a fetal BM-like microenvironment. To determine
if the reduction in HSPCs occurred in the developing fetus, fetal livers (FL) were harvested
from embryonic stage 14.5 (E14.5) and the number of HSPC determined by flow
cytometry. Gross inspection revealed that FLs from Crbn-/- mice (n=4) were visibly smaller
than those from Crbn+/+ mice (n=4) and the total number of cells significantly decreased
(Figure 23A). Moreover, flow cytometry characterization of the distinct hematopoietic
precursor cells showed that all primitive populations, including LT-HSCs (Figure 32A),
were significantly reduced. Interestingly other non-hematopoietic cell populations were
modestly reduced, in absolute cell numbers, these differences did not reach statistical
significance. These data suggest that CRBN controls HSC development from primitive
hematopoiesis.
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Figure 23. CRBN deficiency provokes loss of HSC in fetal liver. Fetal livers (FL)
were harvested from Crbn-/- (n=4) and Crbn+/+(n=4) fetuses at E14.5. (A)
Representative scatter plot showing LSK frequencies measured by flow cytometry. (B)
Stem and progenitor absolute cell counts were extrapolated from frequencies measured
via flow cytometry and whole FL counts. Multiple Student’s t-test per population was
performed and significance achieved at *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001

CRBN controls HSC stemness associated molecules and stimulates quiescence
Multipotent HSCs can differentiate into a limited range of cell types compared to
the relative potency of embryonic stem cells, but express “stem-associated” genes that
maintain homeostasis by controlling the balance of self-renewal and differentiation. A
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“stemness” gene signature consisting of Tek(gene that encodes TIE2), Mpl, Gata1, and
Notch1 is characteristic of the multipotent HSC population at the top level. Indeed, TIE2
controls HSC quiescence within the stem cell niche, a function that is critical for
maintenance of the stem cell compartment and make them resistant to drugs (such as 5fluroruricil, 5-FU) that induces apoptosis in actively cycling cells [91]. Using FACs-purified
LSKs from adult bone marrow, RNA-seq analyses and qPCR validation from purified LTHSC was performed to examine a documented “stemness”-related gene signature[147].

A

B

C

D
LT-HSC

E

Figure 24. CRBN deficiency leads increased HSC proliferation. (A) Femurs and tibias
were harvested from Crbn-/-(n=7) and Crbn+/+(n=7) mice. Following lineage depletion cells
were stained with flow panel (Table13) and FACs-sorted into Lin+, Lin-, LSK, MPP, STHSC & LT-HSC. RNA was isolated and cDNA synthesized, and qRT-PCR performed to
assess mRNA expression of stemness-related genes Tek, Mpl, Notch1, Gata1. Gene
expression was normalized to ΔΔCT values obtained from control gene, β2M and then
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normalized to Crbn+/+ LSK cells. (B) Lin-, LSK, MPP, ST-HSC & T-HSC (C) proliferation
levels from Crbn-/- (n=5) and Crbn+/+ (n=3) mice were measured via in vivo BrdU labelling.
Percent BrdU+ (B-C) and geometric mean fluorescence intensities (gMFI) (D) are
graphed. (E) Histograms of forward scatter area from Crbn-/- and Crbn+/+ LSK and LTHSC. Multiple Student’s t-test per population was performed and significance achieved
at *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001
Interestingly, Crbn-/- HSCs showed a markedly lower level of “stemness” gene
expression consisting of Tek, Gata1, Mpl, and Notch1 (Figure 24 A) suggesting that
CRBN is required to maintain cells in the quiescent, undifferentiated state.
Given the reduction in TIE2 and other stem-related genes that control quiescence,
steady state proliferation of adult bone marrow stem and progenitor cells was examined
using in vivo labeling with 5-bromo-2’-deoxyuridine (BrdU), a thymidine analog that is
incorporated into cycling cells.

Crbn-/- (n=5) and Crbn+/+ (n=3) mice were injected

intraperitoneally with (IP) BrdU and then femoral and tibial bone marrow cells harvested
and analyzed after 18 hours to detect actively dividing cells. The percentage of each cell
population labeled with BrdU was then assessed via multiparameter flow cytometric
analysis. Interestingly, no appreciable differences of the percent of BrdU positive cells
was detected among Lin-, LSK, MPP and ST-HSC populations (Figure 24B), but a
significant increase in proliferating BrdU positive LT-HSC (p=0.01) was detected in Crbn/-

(16.9% ± 2.08) compared to Crbn+/+ LT-HSC (10.5% ± 2.21)(Figure 24C). Interestingly,

all CRBN-deficient stem and progenitor cells had decreased DNA-content as
demonstrated by a significant reduction in the geometric mean fluorescence intensity of
BrdU in each population (Figure 24D) and smaller cell size as shown by forward scatter
plots of bone marrow cells from Crbn+/+ versus Crbn-/- mice(Figure 24E). Since cellular
quiescence is essential for maintenance of stem-like properties in hematopoietic stem
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cells, an increased in LT-HSC proliferation may be responsible for lower detectable LTHSC numbers in the bone marrow of CRBN-deficient mice through enforced
differentiation.

CRBN’s role in differentiation in homeostatic and transplant models
CRBN regulates hematopoietic stem cell quiescence in adult bone marrow and is
required for normal HSC development during embryogenesis. Next complete blood
counts (CBCs) from Crbn-/- mice showed a significant increase (p=0.0027) in total white
blood cells (WBC) compared to Crbn-/- littermates (Figure 25A). Moreover, there was a
statistically significant increase in lymphocytes (p= 0.0297) (Figure 25B), and a modest
increase in monocytes (Figure 25C) (p=0.29) and neutrophils (Figure 25D) (p=0.11) that
did not reach statistical difference. In contrast, basophils (data not shown), eosinophils
(data not shown) and platelets were similar in Crbn+/+ and Crbn-/- mice. Striking decreases
were noted in total red blood cells (RBCs) (Figure 25E) (p= 0.0002) with a corresponding
increase in reticulocytes (Figure 25F) (p= 0.0075) indicating an induction in
erythropoiesis. While there is a normocytic anemia present, hemoglobin and hematocrit
were not impacted by genotype. Together these data suggest that CRBN increases
mature cell output in the white blood cell lineages and has a substantial impact on
erythropoiesis.
To further investigate the role of CRBN in mature cell output we examined
splenocyte count from Crbn-/- and Crbn+/+ mice at 8 to 14 weeks. Crbn-/- had a significant
increase in absolute cell splenocytes numbers (89.25x107± 2.63x107/spleen, p= 0.0216)
in comparison to their control littermates (67.56 x107± 2.16x107/spleen) (Figure 25G).
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Figure 25. CRBN-deficient HSC have increased differentiation capacity both in vivo
& in vitro. Complete blood counts (CBCs) from submandibular bleeds from Crbn-/- (n=29)
and Crbn+/+ (n=30) mice at 2 to 3 months. White blood cells (WBC) (A), lymphocyte
(Lymph) (B), monocyte (Mono) (C), neutrophil (Neut) (D), red blood cell (RBC) (E) and
reticulocyte (F) counts were measured. (G) Splenocyte counts from Crbn+/+ (n=15) and
Crbn+/+ (n=13) mice. Histological appearance of the spleen of 6-month-old Crbn+/+ mice
(H, J) and age-matched Crbn-/- mice (I, K). Lymphoid follicles with germinal centers (H&I,
arrows) and basophilic corona (J&K, upper arrows), surrounded by a cellular marginal
zone (J&K, lower arrows) from Crbn-/- and Crbn+/+ spleens. Histological appearance of
the kidney of 9-month-old Crbn+/+ mice (L) compared to that of age-matched Crbn-/- mice
(M), and that of 24-month-old Crbn-/- mice (N). Tubular epithelium in Crbn-/-mice had
foamy, vacuolated cytoplasm (M, lower right arrow), or were intensely eosinophilic (M,
upper right arrow), or were cuboidal, basophilic with nuclear crowding M, upper left arrow)
(N, upper left arrow). Glomeruli of Crbn-/- mice had increased mesangial matrix,
thickening of capillary basement membranes, and increased cellularity (M, lower left
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arrow) (N, paired lower right arrows), compared to WT controls (L) (L-N, each 630X). (O)
Whole bone marrow from Crbn-/- (n=3) and Crbn+/+(n=3) femurs and tibias were seeded
into methylcellulose medium containing (SCF, IL6, IL3, EPO) and colonies counted 7 days
later. Multiple Student’s t-test per population was performed and significance achieved at
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001
Next various tissues harvested from 3,6 ,9 and 24 month-old Crbn-/- and matched
Crbn+/+ littermates (n=3/genotype per age group(3,6,9); 3 Crbn-/- mice at 24 month-old)
including lung, kidney, bone marrow, liver, spleen, lymph node, salivary glands, pancreas,
thymus, large intestine, and adrenal gland were evaluated.

Based on histological

examination of hematoxylin & eosin (H&E) stained sections, CRBN was found to be
dispensable for gross bone marrow and splenic architecture and bone marrow cellularity
at 3 months (data not shown). However, at 6 months and older Crbn-/- spleens appeared
more cellular and reactive with prominent lymphoid follicles with germinal centers (Figure
25I, arrows) and densely basophilic corona (Figure 25K, upper arrows), surrounded by a
broadly cellular marginal zone (Figure 25K, lower arrows) compared to that of Crbn+/+
mice (Figure 25H,J) with less basophilic corona (Figure 25J, upper arrow) and a narrow,
indistinct marginal zone (Figure 23J, lower arrows) suggesting leukocyte infiltration
(Figure 25H-K). Crbn-/- kidneys had evidence of glormeulonephritis with tubular injury and
regeneration at 9 months (Figure 25M) which was heightened by 24 months. Crbn-/- mice
(9 of 12) ages 3-24 months, but not Crbn+/+ mice (0 of 9) ages 3-9 months old had rare,
mild, focal mononuclear leukocyte infiltrates in the liver, salivary gland, lung and/or
kidney.
To further evaluate the differentiation capacity of mature hematopoietic
progenitors, cells that were present in roughly equal frequencies in bone marrow, a shortterm colony-formation assay in methylcellulose was performed. Equal numbers of WBM
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(1x105) were seeded in methylcellulose media supplemented with a cocktail of
recombinant cytokines (SCF, IL3, IL6, EPO). After 7 days in culture, we observed a
significant increase in the total colony counts generated from Crbn-/- (193.3 ± 24.01,
p=0.0185) compared to Crbn+/+ bone marrow (Figure 25O). Although this does not
evaluate long-term colony forming units or stem cell fitness/function, the distribution
capacity for differentiation in vitro and response to hematopoietic growth factors was
superior in Crbn-/- bone marrow which suggests while there is no obvious bone marrow
failure phenotype present in Crbn-/- mice, they have impaired stem cell quiescence, lower
stem-related gene expression, and greater proliferation.

CRBN ablation does not impair fitness and reconstitution capabilities in adult mice
A hallmark of HSC fitness and function is the ability to fully repopulate lethally irradiated
recipients either in a competitive or non-competitive transplantation. First, we investigated
whether bone marrow homing (BM seeding) of intravenously injected HSPCs is impaired
using carboxyfluorescein diacetate succinimideylester (CFSE) labeling (Figure 26A).
CD45.2+ CFSE-labeled Lin- cells from Crbn-/- and Crbn+/+ were transplanted into lethally
irradiated WT (CD45.1) recipients. We found that Crbn+/+ and Crbn-/- HSPCs showed
equivalent homing capacities based on the recovery of equal frequencies of CFSE+ cells
after 18 hours (Figure 26B).
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Figure 26. CRBN ablation does not impair HSPC homing to bone marrow. (A)
Experimental design. (B) CFSE-labelled Lin- cells were transplanted into lethally
irradiated mice. Relative percent of CFSE+ Crbn-/- (n=7) HSPCs to Crbn+/+ (n=6) HSPCs
was graphed. Graph depicts combination of 2 experiments. Multiple Student’s t-test per
population was performed and significance achieved at *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001

Based on these homing experiments, a serial competitive chimeric transplantation
experiment (Figure 27A) was conducted using WBM (1x106 cells) from Crbn-/- or Crbn+/+
mice (CD45.2) combined with WBM (1x106 cells) from Crbn+/+ (CD45.1) in a 1:1 ratio
transplanted into lethally irradiated WT (CD45.1) mice. We observed a significant
decrease in donor engraftment (percent of CD45.2+ donor cells) in the peripheral blood
(PB), spleen (Sp) and bone marrow (BM) in recipients that received WBM from Crbn-/-
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mice (Figure 27B-D, H). Multi-lineage donor chimerism in the spleen also declined in
animals that received Crbn-/- WBM (Figure 27E-F).
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Figure 27. CRBN-deficient HSCs do not outcompete control HSC in 3:1 ratio in
competitive primary bone marrow transplant. (A) Experimental design. One million
WBM cells from Crbn-/- (n=3) or Crbn+/+ (n=3) CD45.2 were mixed with 1X106 cells from
control CD45.1 mouse and transplanted into lethally irradiated CD45.1 recipients (n=10
per genotype). (B) Peripheral Blood (PB) chimerism was monitored over time and
endpoint (4 months post bone marrow transplant (BMT) (C). (D) Total spleen, T cell (E),
B cell (F) and macrophage (G) chimerism at endpoint. (H) Total BM, Lin- (I) and LSK (J)
chimerism was analyzed at endpoint. Multiple Student’s t-test per population was
performed and significance achieved at *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001
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Figure 28. CRBN-deficient HSCs do not outcompete control HSC in 3:1 ratio in
competitive secondary bone marrow transplant. (A) Experimental design. WBM
(1x106) cells from primary Crbn-/- (n=10) and Crbn+/+ (n=10) recipients were and
transplanted into lethally irradiated CD45.1 recipients (n=10 per genotype). (B)
Peripheral Blood (PB), Spleen (C) and BM (D) chimerism at endpoint (4 months post
bone marrow transplant (BMT). (E) Lin-, LSK, MPP, ST-HSC, LT-HSC, T cell B cell and
myeloid chimerism at endpoint was determined. Multiple Student’s t-test per population
was performed and significance achieved at *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001
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Notably, while the total number of donor-derived LSKs in the BM of recipients receiving
Crbn-/- WBM was significantly reduced (p<0.05) (Figure 27J), the total number of donorderived Lin- cells remained similar between recipients receiving Crbn+/+ WBM (Figure
27I). These data suggest superior differentiation of mature populations by Crbn-/- bone
marrow, but significantly fewer functional LT-HSCs with repopulation capacity.
As expected upon secondary transplantation (Figure28A), animals that received
WBM from primary Crbn-/- WBM recipients experienced further diminution in bone marrow
chimerism (from levels seen in the primary recipients) in PB, Sp and BM (Figure 28B-D).
Moreover, donor-derived HSPCs were virtually exhausted at 4 months post-transplant
(Figure 28E) and donor-derived T, B and myeloid cells in the BM were drastically reduced
(Figure 28E).
Overall despite their increased differentiation potential, Crbn-/- HSCs were unable
to compete with Crbn+/+ HSCs following competitive serial transplantation. It is important
to note that the competitive transplant was performed using a 1:1 ratio of Crbn+/+:Crbn-/WBM cells; whereas, the HSC ratio was approximately 3:1 (Crbn+/+:Crbn-/-).

Long-term reconstitution potential is enhanced by CRBN depletion in LT-HSC
Next, the role of CRBN in LT-HSC reconstitution was expressly examined in noncompetitive serial transplantation with a saturating dose of purified Crbn-/- LKs (Lin-c-Kit+)
or Crbn+/+ LKs.

Following lethal irradiation, one million purified LKs were injected

intravenously into congenic WT recipients (CD45.1) (Figure 29A).
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Figure 29. CRBN deficiency does not impair HSC reconstitution potential in noncompetitive serial transplants. (A) Experimental design. Lin-c-Kit+ (LK) (1x106) cells
were harvested from Crbn-/- (n=7) and Crbn+/+ (n=6) CD45.2 mice and transplanted into
lethally irradiated CD45.1 recipients. (B) Perohepral blood (PB), spleen (Sp), and bone
marrow (BM) chimerims after 3 months was determined. Crbn-/- and Crbn+/+ recipients
were pooled per genpotype and WBM (1x106) cells were transplanted into secondary
recipients. (C) Perohepral blood (PB), spleen (Sp), and bone marrow (BM) chimerims
after 3 months was determined. (D) HSPC absolute cell counts extrpolated from flow
cytometric analyses from secodary recipients from (C). Multiple Student’s t-test per
population was performed and significance achieved at *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001
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Repopulation dynamics (donor engraftment and donor-derived HSPC numbers) were
largely similar during the primary and secondary transplant suggesting that high LKs, and
thus higher LT-HSC numbers (Figure 29B-D) showed limited impact on spleen and bone
marrow engraftment.
However, in tertiary transplantations, recipient mice with control LKs exhibited
lower PB, spleen and BM reconstitution compared to Crbn-/- LK recipients (Figure 30 A,
C, E). Crbn+/+ LKs undergo exhaustion due to proliferative stress and demand for
continuous self-renewal potential resulting in a significant decrease in all donor-derived
HSPC frequencies and total cell numbers in the BM (Figure 30G-H) of recipient mice.
Intriguingly, recipient mice receiving Crbn-/- LKs maintained significantly higher numbers
of long-term multi-lineage cells. Compared to the defects observed in the fetal liver and
adult bone marrow (Figure 30 B, D, F), significant myeloid skewing in the peripheral blood,
spleen and bone marrow suggests that CRBN may play a different role in embryonic
development compared to mature hematopoiesis.
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Figure 30. Long-term reconstitution capacity is enhanced by CRBN ablation in
HSCs. Secondary recipients from Figure 29 were pulled per genotype and transplanted
into tertiary CD45.1 recipients (n=15 per genotype). (A, C, E) PB, Sp and BM chimerism
at endpoint (4 months). T cell, B-cell and myeloid chimerism at endpoint from PB (B), Sp
(D), BM (F) at endpoint. HSPCs donor-derived absolute counts (G) and chimerism (H)
measure by flow cytometric analysis. Multiple Student’s t-test per population was
performed and significance achieved at *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001
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To further clarify these conflicting results, we examined HSC frequencies in Crbn-/- mice
and evaluated the vasculature of mature adult animals. Femurs from Crbn-/- (n=5) and
Crbn+/+ (n=5) mice were harvested, formalin-fixed, decalcified, embedded, sectioned and
then stained for the presence of CD34+ vascular endothelial cells. Crbn-/- bone marrow
expressed a modest but significant increase in CD34+ vessels per field of view at 20X
(Figure 31A). The hypoxic character of LT-HSCs is determined by their position within the
BM so we next determined if CRBN-deficient HSC localize normally to the hypoxic bone
marrow regions using HypoxyprobeTM (pimonidazole hydrochloride) staining which
detects cells under <5% of oxygen (O2). Crbn-/- (n=4) and Crbn+/+ (n=4) mice were injected
(IP) with pimonidazole HCl (60mg/kg) and bone marrow was harvested after 90 minutes
and stained for anti-pimonidazole conjugated to FITC. Using flow cytometry, no significant
differences in pimonidazole staining was observed among Crbn-/- and Crbn+/+ HSPC
populations (Figure 31B).
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Figure 31. CRBN deficiency modestly increases vasculature. (A) Femurs from Crbn/(n=5) and Crbn+/+ (n=5) littermates were harvested, formalin fixed (18 h), decalcified,
sectioned and stained via immunohistochemistry (IHC) and analyzed for the presence
of CD34+ vascular endothelial cells. The number of CD34+ vasculature seen per field
of view at 20X per mouse per genotyped was determined and graphed. Multiple
Student’s t-test per population was performed and significance achieved at *p<0.05,
**p<0.01, ***p<0.001, ****p<0.0001 (B) Crbn-/- and Crbn+/+ were injected (i.p.)with PBS
(n=1 per genotype) or pimonidazole (pimo). BM was harvest 90 minutes later and
percent of pimo positive cells in Lin-, LSK and LT-HSC was assessed via flow cytometry
and graphed. FMO= fluorescence minus one control. One-way ANOVA followed by
Dunnett’s multiple comparison was performed and significance achieved at *p<0.05,
**p<0.01, ***p<0.001, ****p<0.0001

CRBN reduces HSC’s response to transcription and translation arrest
As indicated at steady state and in the fetal liver, Crbn-/- HSCs are reduced in
frequency but more commonly in cell cycle (studied on in adult bone marrow). Cycling
cells are selectively sensitive to the effects of 5-fluorouracil (5-FU), a pyrimidine analog
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that interferes with DNA and RNA synthesis, relative to quiescent primitive multipotent
progenitor cells. Next, Crbn-/- and Crbn+/+ mice were exposed to weekly challenges of 5FU (150mg/kg) and survival was monitored (Figure 32A). Lethality occurred in all Crbn-/mice (10 of 10) following 5-FU challenge compared to only three Crbn+/+ mice (3 of 10)
(p<0.001) (Figure 32B). Despite having higher baseline WBCs, Crbn-/- mice had
significantly less WBCs (Figure 32C) and all other mature populations (data not shown),
after two doses of 5-FU. HSPC numbers after the 1st (Figure 32D) and 2nd (Figure 32E)
5-FU dose were significantly (p<0.05) lower in the Crbn-/- compared to Crbn+/+ mice.
Since 5-FU primarily blocks DNA and RNA synthesis, but can also induce DNA
damage, we administered two doses of 5-FU and monitored multi-lineage reconstitution
in the PB overtime. Interestingly, WBC counts and HSPC numbers in Crbn-/- mice were
fully restored to control levels 18 days post 2nd 5-FU (Figure 32F-G) strongly suggesting
that CRBN deficiency was related to higher nucleic acid synthesis caused by greater
proliferation and not from irreversible DNA-damage. Remarkably, despite their almost
undetectable levels after the 2nd 5-FU challenge, Crbn-/- HSPC numbers were restored
(trending decrease compared to Crbn+/+ HSPC, p=0.14) demonstrating that Crbn-/- do
indeed have a remarkable ability for differentiation and self-renewal in the mature adult
bone marrow.
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Figure 32. Increased HSC proliferation sensitizes CRBN-deficient HSCs to 5-FU
treatment (A) Experimental design. Crbn-/- (n=10) and Crbn+/+ (n=10) littermates were
dosed with weekly challenges of 5-FU. (B) Survival overtime. P value was determined
using Mantel-Cox Log-rant test. (C-G) Crbn-/- (n=15) and Crbn+/+ (n=16) littermates were
given 2 doses (1 dose per week) of 5-FU. Five days after each dose, BM from randomly
selected 3-4 mice per genotype was harvested and HSPC absolute counts and complete
blood counts were measured. (C) White blood cell counts (WBCs) at baseline and
following 2nd Injection. HSPC absolute counts from 1 femur and 1 tibia after the 1st (n=3
per genotype) (D) and 2nd challenge (n=2-3 per genotype) (E). (F) WBC counts measured
over 131 days after 2nd 5-FU challenge (n=5-6 per genotype) via CBCs. (G) HSPC
absolute counts (using Trumpp et al classification[66]) from 1 femur and 1 tibia (n=3 per
genotype) eighteen days after 2nd 5-FU challenge. Multiple Student’s t-test per population
was performed and significance achieved at *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
97

Control of CXCR4 is associated with LT-HSC regulation
Detailed analysis of fetal and adult hematopoiesis has shown a critical role for the
niche, localization, and homing. We found that Crbn-/- cell homing to adult bone marrow
was normal.

However, there is a critical role of CXCR4/CXCL12 in immature

hematopoiesis in the adult bone marrow[87] and fetal liver[86]. CXCR4 is a G proteincoupled chemokine receptor that binds to classical chemokines and nonclassical
activating ligands. Although Cxcr4 germline deficient mice are perinatally lethal due to
gross organ defects[148], there is a dramatic defect in definitive HSC development in the
fetal liver due to changes in recruitment, survival and expansion in the fetal BM
environment that was associated with diminished stemness, activation, and sensitization
to 5-FU[86]. CXCR4 deficient fetal liver cells also showed an increase in cycling HSPC
and granulocytes in peripheral blood. Re-expression of CXCR4 repaired the defect and
normalized hematopoiesis suggesting that this does not induce stem cell exhaustion or
depletion long-term.

Moreover, CXCR4 haploinsufficient HSPCs had a competitive

repopulating advantage. Therefore, CXCR4 and other adhesion factors important for
niche localization, including VCAM-1, were examined in the LT-HSCs and other purified
hematopoietic cell populations from adult Crbn-/- and Crbn+/+ bone marrow. All Crbn-/HSPCs (only LT-HSC shown) and Lin+ had a significant decrease in Cxcr4 mRNA
expression (Figure 33A). CRBN deficiency also provoked loss of Vcam1 mRNA
expression in LT-HSC but no differences in other HSPC and mature populations (Figure
33A). These results were particularly interesting because VCAM-1 deletion has been
shown to result in increased egress from the BM with elevated presence in the peripheral
blood of immature lymphocyte [149]. Furthermore, thalidomide treatment in endothelial
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cell line, HUVEC, resulted in downregulation of TNFα-induced expression of ICAM-1
(CD54), VCAM-1 (CD106) and E-selectin antigens[150] supporting the proposition that
CRBN may regulate cell adhesion molecule expression on HSCs.

B

A

C

Figure 33. CRBN deletion alters transcription factor profiles of HSPCs. (A) Femurs
and tibias were harvested from Crbn-/-(n=7) and Crbn+/+(n=7) mice. Following lineage
depletion cells were stained with flow panel (Table13) and FACs-sorted into Lin+, Lin-,
LSK, MPP, ST-HSC & LT-HSC. RNA was isolated and cDNA synthesized, and qRT-PCR
performed to assess mRNA expression of adhesion-related genes Cxcr4 and Vcam1.
Gene expression was normalized to ΔΔCT values obtained from control gene, β2M and
then normalized to Crbn+/+ Lin+ cells. (B) Dysregulated transcription factors determined
by pathway analysis (EnrichR) of RNA-sequencing results from purified Crbn-/- or Crbn+/+
LSKs. (C) mRNA expression of Akt1, Myc and Hi1α from Crbn-/- and Crbn+/+ Lin+ and LTHSC. Multiple Student’s t-test per population was performed and significance achieved at
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
Metabolic cues are often orchestrated by niche cells through secreted factors,
hypoxia, or cell-to-cell interactions including CXCR4/CXCL12 and VCAM-1/αβ-Integrins
axes[151-154]. Metabolically activated HSCs are poised to undergo lineage priming and
differentiation which results in reduction in stem-related genes[152]. Metabolic status of
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HSPCs was analyzed using pathway analysis generated from RNA-sequencing results
of purified Crbn-/- and Crbn+/+ LSKs. Key metabolic pathways, ESR1, MYC, ATF2, HIF1α,
HDAC2, TP53, EZH2, ESR2[155-161], were dysregulated between Crbn-/- and Crbn+/+
LSKs (Figure 33B). Quantitative RT-PCR validation confirmed CRBN deficiency
stimulates metabolic activity as indicated by increased Akt1 (Lin+ p<0.0001, LT-HSC
p<0.05) and Myc (Lin+ p<0.0001, LT-HSC p<0.05) mRNA expression accompanied by
decreased Hif1α (Lin+ p<0.05, LT-HSC p<0.0001) mRNA levels in Crbn-/- Lin+ and LTHSC (Figure 33C). Collectively, the genetic signatures of Crbn-/- LT-HSC resemble that of
activated HSC[152, 162].

CRBN loss in niche cells does not alter hematopoiesis
As HSC extrinsic-induced alterations in niche interactions can influence cell cycle
and therefore HSC maintenance, the impact of CRBN deletion in the bone marrow niche
was examined using a transplantation model. Whole bone marrow from control congenic
mice (CD45.1) was transplanted into lethally irradiated Crbn-/- (n=15) or Crbn+/+ (n=13)
mice (CD45.2) recipient mice.

Peripheral blood chimerism and multi-lineage

reconstitution were monitored over time (Figure 34A). There were no differences between
Crbn-/- and Crbn+/+ recipients in frequencies of donor derived cells in PB, Sp or BM (Figure
34B, E-F)), mature blood cell output in peripheral blood (Figure 34C-D) or HSPC numbers
in the bone marrow at endpoint (Figure 34G). These data show that the impact on HSPCs
is likely to be driven by an intrinsic role for CRBN in hematopoiesis rather than the
regulation of the bone marrow environment.
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To test if the difference in response to 5-FU treatment is dependent on the bone
marrow niche, we transplanted congenic control WBM cells into lethally irradiated Crbn-/and Crbn+/+ mice and administered 3 doses of 5-FU three months post BMT (Figure 35A).
There were no observable differences in white blood cell output (Figure 35B) or survival
(Figure 35C). However, both Crbn-/- and Crbn+/+ succumbed to bone marrow failure, likely
due to impaired niche function from the combined effects of irradiation and 5-FU.
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Figure 34. CRBN deficiency in niche cells does not impact hematopoiesis. (A)
Experimental design. Wild-type whole bone marrow (WBM) (1x106) CD45.1 cells were
transplanted into lethally irradiated Crbn-/- (n=15) or Crbn+/+ (n=13) CD45.2 recipients. (BD) Peripheral blood chimerism and complete blood counts (only WBC & Lymph shown)
overtime by determined flow cytometric analyses. (E) Spleen and BM (F) chimerism and
HSPC absolute cell counts (G) at endpoint (n=3-5 per genotype). Multiple Student’s t-test
per population was performed and significance achieved at *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001.
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Figure 35. CRBN deficiency in niche cells does not alter stress hematopoiesis. (A)
Experimental design. Randomly selected cohort from Figure 34; Crbn-/-(n=5) and Crbn+/+
(n=7) were injected with 3 doses (1 per week) of 5-FU 3 months after initial bone marrow
transplant (BMT). (B) Peripheral WBC counts were determined one day before 1st 5-FU
dose and 1 week after 2nd 5-FU dose via flow cytometry. Multiple Student’s t-test per
population was performed and significance achieved at *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001. (C) Survival overtime. P value was determined using Mantel-Cox Log-rant
test.

Figure 36. Visual Abstract
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Discussion:
Hematopoietic stem cells transplantation (HSCT) from an HLA matched allogeneic
donor or from autologous bone marrow can restore the functional hematopoietic system
and blood cell production[163]. As such, HSCT has become the gold standard for the
treatment of many neoplastic and nonmalignant disorders. However, three major
obstacles impede its widespread success: 1) disease relapse, 2) graft-versus-hostdisease (GVHD) (in allogeneic HSCT), and 3) a shortage of HSC due to limited HLAmatched donors (in allogeneic HSCT) and unsuccessful in vitro expansion of HSC (in
both allogeneic and autologous HSCT).

Understanding the molecular mechanisms

governing HSC cell fate and quiescence could facilitate successful in vitro expansion of
HSCs and enable the application of HSCT for the treatment of various hematologic and
genetic diseases.
Del5q MDS is a pathological disease that arises from hematopoietic stem cells
harboring

somatically-acquired

chromosomal

abnormalities[18].

These

highly

proliferative mutant clones give rise to abnormal immature myeloid cells that colonize the
bone marrow and inhibit normal HSC function.

BM hypercellularity and peripheral

cytopenia is the resultant phenotype in these patients[164].

Primarily del(5q), but also

non-del(5q), MDS patients are sensitive to lenalidomide (one of the IMiD® drugs) where
it reduces the malignant stem cell population but increases erythropoiesis [43, 141, 165,
166]. Lenalidomide treatment in non-del(5q) MDS patients leads to an increase in
erythropoietin (EPO) receptor signaling that stimulates erythropoiesis. In del(5q) MDS,
the frequency of cytogenetic and erythroid response is higher due to multiple mechanism
of action of lenalidomide treatment in these patients through synthetic lethality. The
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del(5q) clonal disorder causes haploinsufficiency of many deleted genes including
CK1α[167]. Lenalidomide-dependent cereblon-mediated degradation of CK1α induces
lethality in the aberrant del(5q) clones [30] and restores effective erythropoiesis through
eradication of the malignant clone while simultaneously increasing erythropoietin
promoting activity in non-malignant clones. Furthermore, lenalidomide treatment
provokes other hematologic responses such as an increase in CXCR4 expression on
CD34+ HSPCs, increased differentiation of CD34+ HSPCs characterized by a decrease
in CD34+ HSPCs and an increase circulating lymphocytes with increased effector
function[141, 166]. These data suggest a regulatory role of cereblon in hematopoiesis
perhaps via CXCR4/CXCL12 axis.
In a similar manner, in this study we have identified CRBN as a novel regulator of
HSC maintenance. CRBN deficiency in HSC causes a loss of long-term HSCs in the bone
marrow characterized by increased proliferation, improved repopulation capability in a
non-competitive environment, white blood cell expansion in the periphery as well as a
genetic signature that confers decreased dormancy.
Although we did not identify any birth defects in Crbn-/- mice, there was a consistent
decrease in their weight (Figure 20B) that becomes more apparent at older ages (data
not shown). CRBN deficiency alleviated high fat diet (HFD)-induced weight gain (data not
shown) suggesting a metabolic regulatory function of CRBN. Indeed pathway analysis
data comparing differentially expressed transcription factors between Crbn-/- to Crbn+/+
LSKs highlights many metabolic regulators (ESR1, MYC, ATF2, HIF1α, HDAC2, TP53,
EZH2, ESR2[155-161]) as altered. Validation of expression levels of these crucial
metabolic regulators should be confirmed on purified LT-HSC via single cell
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transcriptional analysis or total seq for both mRNA and protein analysis.

Though

preliminary, a slight elevation in mRNA expression of c-Myc and Akt1 observed was in
Crbn-/- LT-HSC supporting the possibility that Crbn-/- HSC have altered metabolic function.
Our laboratory recently investigated CRBN’s role in regulating T cell function and showed
that it acts to harness effector T cell metabolism. Metabolism induced through antigen
engagement in CD8+ T cells influences the quality and durability of the response and
controls pathogen clearance and memory development. Interestingly, CRBN has the
highest level of mRNA and protein expression in resting cells and then rapidly declines
following T cell receptor (TCR) engagement. Moreover, its expression is highly induced
later in the activation response which is consistent with its regulatory role (Hesterberg et
al, manuscript under review).

Our study along with our data suggests that CRBN

expression may be required for maintaining a metabolically inactive state (dormancy in
LT-HSC).
Previous studies have demonstrated the importance of low mitochondrial activity
to the preservation of HSC quiescence and in the prevention of HSC exhaustion [152,
168-174]. Crbn-/- HSCs showed a modest but significant increase in BrdU staining
coupled with enhanced differentiation capacity and sensitivity to 5-FU treatment
suggesting that Crbn-/- HSCs are in a “primed” state, dubbed “GAlert” cycle state (neither
quiescent nor activated) by Rodgers et al[98]. The GAlert state is described as a
subdivision of G0 cell cycle state that is characterized by a distinct transcriptional profile
and an accelerated response to physiological stimuli[98, 175, 176].Though further genetic
and proteomic investigation of purified Crbn-/- and Crbn+/+ LT-HSC is required, Crbn-/HSC appear to be poised for activation.
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Aggregate results suggest that HSC pools are replenished through symmetric cell
division (SCD) and differentiate through asymmetric cell division (ACD). Cues that define
these cell fates are under investigation but can be either cell-intrinsic (pre or post-mitosis)
or niche-directed. Recent evidence suggests that cell intrinsic pre-mitosis determinants
dictate HSC division[177, 178]. At each developmental stage (embryonic (E14.5), adult
and aged) Crbn-/- LT-HSC frequencies and counts are significantly lower than controls
even at older ages when LT-HSC expansion has been demonstrated [97, 143, 144, 177].
Hence, we propose that cell-intrinsic factors controlled by CRBN determine the type of
HSC division, and therefore, the size of the HSC pool.
HSC retention in the bone marrow and development from fetal liver is controlled
by cell autonomous and extrinsic factors. Cell-to-cell interactions between HSCs and
niche cell are thought to be the primary mechanism of HSC retention in the bone marrow.
In adult bone marrow, niche cells such osteoblasts, CAR cells, sympathetic neurons
vascular endothelial cells, and sinusoidal endothelial cells (SECs) express a number of
receptor molecules including, N-cadherin, VCAM-1, CD44, membrane-bound stem cell
factor and secrete a number of ligands CXCL12, ANG1, THPO that collectively anchor
HSCs in their dormant niches[86, 87, 162]. Additionally, HSCs express various receptors
CXCR4, VCAM-1, VLA-4, TIE2, MPL, and NOTCH-1 that either directly interact with
receptors on the niche cells or respond to factors secreted by them to control localization
and dormancy during steady-state[99, 162, 179-183]. Crbn-/- HSC have a significant
reduction in a number of these factors which may contribute to their phenotype in adult
BM and fetal liver. Because the loss of HSC is observed at embryonic stages, we propose
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that the production, retention and activation of HSC in adult bone marrow is contributing
to the low numbers observed in Crbn-/- adult mice.
Despite their enhanced mature cell output in the peripheral blood and the increase
in leukocyte infiltration at older ages, Crbn-/- mice neither exhibit bone marrow failure nor
decreased survival from autoimmune-related conditions. Left unperturbed, no changes in
long-term survival were observed between Crbn-/- and Crbn+/+ littermates. While
additional stress-hematopoiesis inducing methods such as exposure to mobilization
factor, GM-CSF, or inflammatory endotoxin, lipopolysaccharides (LPS), will determine if
CRBN deficient HSCs have impaired response to stress or injury, their ability to restore
mature and HSPC numbers after

limited 5-FU exposure and non-competitive

transplantation suggest CRBN deficient maintain effective response to non-DNA
damaging injury.
In conclusion, our results show that CRBN is an emerging regulator of HSC that
may have therapeutic implications in hematological malignancies including the
modulation of cell-adhesion mediated drug resistance, differentiation/activation of drugresistant malignant blast cells/tumor-initiating quiescent cells rendering them more
susceptible to chemotherapy and increasing the persistence of HSC in recipients who
have received HSCT.
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Experimental Procedures
Animal Husbandry
Germline Crbn heterozygous mice (Crbn+/-) were obtained from Dr. Anjali Rajadhyaksha
(Cornell University). Mice were genotyped using methods described by Rajadhyaksha
Lab and all genotyping primers can be found below [122]. C57BL/6 and littermates of
Crbn-/- mice were used as Crbn+/+ controls. Congenic mice, B6.SJL-Ptprca Pepcb/BoyJ
(CD45.1), were ordered from Jackson Lab (Cat# 002014). All animals were maintained
under specific pathogen-free conditions and fed with standard diet. Use of these mice
was governed by a research protocol approved by the Institutional Animal Care and Use
Committee and all mice were bred and maintained at the H. Lee Moffitt Cancer Center
and Research Institute (IACUC protocols IS00006028 and IS00004986).
Table 10. Cereblon Genotyping Primers
Mouse strain

Primer

Sequence 5'- 3'

Crbn+/+

Loxf (Wild-Type forward primer)

AGGAGCACTGAACGGCTTACAG

Crbn-/-

F (knockout forward primer)

TTGTTTCAGAACTGCTGGGATGTG

Crbn+/+
Crbn-/-

Lox R (common reverse primer)

CGCATGCTGACTGATCACAGC

Flow Cytometry Analysis for BM Populations
Mouse BM cells were harvested for flow cytometric analysis using a previously described
protocol[184-187]. Briefly, BM cells were collected from tibias and femurs, lysed using
RBC lysis buffer (# 00-4300-54, eBioscience) and incubated with antibodies for 1 hour on
ice. Viability was determined using DAPI (Invitrogen Corp., Carlsbad, CA) unless
otherwise stated. Mouse peripheral blood was collected from the submandibular vein and
subjected to the same RBC lysis and staining procedure as BM. Flow cytometry was run
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on a FACS LSRII cytometer (BD Biosciences, San Jose, CA) and analyzed with FlowJo
software v10.5.0 (FlowJo LLC, Ashland, Oregon). HSPCs from BM were determined after
antibody (clones, commercial sources, instrument settings, fluorochromes and filters are
described in Table11-12. Total LSK, HSC, and MPP measurements were extrapolated
based on the total BM counts and an established surface marker profile. To analyze
mature populations, mouse BM and peripheral blood samples were incubated with
antibody cocktail listed in Table 11-12. To evaluate donor and recipient populations in BM
transplantation assays, BM, Sp and peripheral blood cells were stained with PE or BV711
conjugated anti-CD45.1 (clone A20, TONBO Bioscience/ Biolegend) and APC/Cy7conjugated anti-CD45.2 (clone 104, TONBO Biosciences). Total LSK, HSC, and MPP
measurements were extrapolated based on the total BM counts and an established
surface marker profile.

Bone Marrow Colony Assays
BM cells (1x105 or 5x104) were suspended in 100-μl RPMI, which was added to 1.5-ml
Methocult medium (# 03444, Stem Cell Technologies) with or without cytokines (# 03231,
Stem Cell Technologies) and vigorously vortexed for 30 sec. When bubbles disappeared
20 min later, Methocult medium was dispensed into 35 mm culture dishes and incubated
at 37°C and 5% CO2. Colonies were observed and counted after incubation for 7 days.

Apoptosis, BrdU & Hypoxia Assays
To examine apoptosis, BM from Crbn-/- (n=5) and Crbn+/+ (n=4) were harvested and
incubate with CellEvent™ Caspase-3/7 (#C10423, Invitrogen Carlsbad, CA) for 30
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minutes and then stained with HSPC panel (Table 13). Percentage of hematologic cells
positive for caspase 3/7 was assessed via flow cytometry.
For BrdU incorporation assay, BrdU (100 mg/kg body weight; BD Biosciences) was
injected intraperitoneally into mice for 16 to 18 h before analysis. BrdU incorporation was
determined by flow cytometric analysis using the BrdU Flow Kit (BD Biosciences)
according to the manufacturer’s instructions.
To investigate hypoxia in the bone marrow, Crbn-/- and Crbn+/+ mice were intraperitoneally
injected with pimonidazole HCl solution (Hypoxyprobe™, #HP2-200Kit, Burlington MA) at
a dosage of 60mg/kg body weight or PBS. Ninety minutes later, BM was harvested and
stained with HSPCs panel then fixed and permeabilize with Cytofix/cytoperm (# 88-882400, eBioscience), then stained with anti-pimonidazole, FITC-conjugated IgG1 mouse
monoclonal antibody (clone 4.3.11.3) and analyzed by flow cytometry.

BM homing assay
Lin- cells were purified from either Crbn+/+ or Crbn-/- mice and were labeled with
carboxyfluorescein succinimideylester (CFSE). CFSE-labeled Lin- (1x106) cells were
transplanted into lethally irradiated (550 cGy, 500 cGy, ~3 h apart) recipients. Recipients
were sacrificed 16 h later and CFSE+ bone marrow populations were quantified by flow
cytometric analysis to determine the percentage of homed cells.

Competitive and non-competitive transplant
Donor BM cells were harvested from either Crbn+/+ or Crbn-/- C57BL/6j-Ptprcb (CD45.2+)
mice and mixed 1:1 with B6.SJL-Ptprca (CD45.1+) BM cells. Adult recipient mice (7-12
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weeks) were lethally irradiated (550 cGy, 500 cGy, ~ 3 h apart) on the day of
transplantation. Recipients received 1.0×106 cells/mouse (i.v.). Peripheral chimerism, and
hematopoietic reconstitution were monitored for indicated times from the submandibular
vein to evaluate donor cell engraftment. BM, Spleen and blood (cardiac puncture)
chimerism were analyzed via flow cytometry at indicated endpoints.
For non-competitive transplant, BM from

In vivo 5-FU challenge
For serial 5-FU treatments, Crbn+/+ (n=15) and Crbn-/- mice (n=16) (8–13 weeks) were
intraperitoneally injected with a single dose (150 mg/kg body weight) of 5-FU weekly,
survival was monitored daily and CBCs weekly. Smaller cohort of mice (n=3) were then
euthanized at indicated time points, and bone marrow cells were isolated and counted.
The proportions of HSPCs were analyzed by flow cytometry and then multiplied by the
total number of bone marrow cells to calculate the absolute number of HSPCs.

Fetal Liver harvest and culture
Six to 8-week-old Crbn+/+ or Crbn-/- breeding pairs were mated at night. The next morning
plugged dams were separated. Fourteen days following the time plug was observed
(E14.5), pregnant dams were humanely euthanized by CO2 inhalation. Fetal livers from
embryos were dissected out under dissection microscope and placed in ice-cold condition
mouse medium[188]. FL were passed through 40-micron cell strainer (#22-363-547,
Fisher Scientific, Hampton, NH) using the plunger from a 3mL syringe (#309657, Becton,
Dickinson and Company). Once single-cell suspension was attained cells were lysed with
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RBC lysis buffer (eBioscience) washed and stained for HSPC panel (Table 13) and
analyzed via flow cytometry.

RNA-sequencing & pathway analysis
Bone marrow (femurs, tibia & iliac crest) from Crbn-/- (n=16) and Crbn+/+ (n=16) were
harvested and pooled into groups of four per genotype (mixed genders, distributed
equally per group). Following BM processing outlined above, samples were stained with
Lineage cocktail, Sca-1 and c-Kit antibodies and LSKs (5x105cells/group) were FAC
sorted using BD Aria. Following two washes, pellets were lysed with RLT Plus buffer
(RNeasy Micro Kit, #74034, Qiagen, Germantown, MD). Total RNA was then harvested
using RNeasy Micro Plus Kit following a modified manufacturer’s protocol with additional
on-column DNase treatment (RNase-Free DNase Set, #79254, Qiagen) prior to elution.
RNA-seq libraries were prepared using the Ovation® SoLo RNA-Seq System (#0501,
NuGen, Redwood City, CA) following the manufacturer’s protocol. Approximately 50M
pairs of 75-base reads per sample were generated on the Illumina NextSeq 500
sequencer. RNA sequence data were aligned to the mouse reference genome mm10
using Tophat2 (PMC2672628). Aligned sequences were assigned to exons using the
HTseq package (PMC4287950) against RefSeq gene to generate initial gene counts.
Normalization,

expression

between Crbn+/+ and Crbn-/- LSKs

modeling,
were

and

differential

expression

performed

using

DESeq2 (PMC4302049). RNAseq quality control was performed to examine read count
metrics, alignment fraction, chromosomal alignment counts, expression distribution
measures using RSeqQC (PMID:22743226), and with principal components analysis and
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hierarchical clustering. Differentially expressed genes were subjected to pathway
analysis using Enrichr (https://amp.pharm.mssm.edu/Enrichr/)

qRT-PCR analysis
Total RNA was extracted using RNeasy Micro Plus Kit (#74034, Qiagen) and used as
templates to synthesize cDNA using iScript cDNA synthesis kit (#1708890, Bio-Rad
Laboratories) according to the manufacturer’s instructions. cDNA was added to Taqman
PCR mix (Life Technologies) in a 12-μL final volume containing forward and reverse
primers. Amplification cycles (n=40) were performed using 7900HT Real-time PCR
System (Applied Biosystems). Primers were purchased from Life Technologies,
Carlsbad, CA. See Table 14 for list of TaqMan primers used. Data were normalized to the
reference gene 18S ribosomal RNA (18S) or β2 microglobulin (B2M) by a relative
quantification using the ΔΔCt method and was measured relative to Crbn+/+ Lin+ cells or
Crbn+/+ LSK (in the instances where the genes were not expressed by Lin+ cells).

Table 11. List of Taqman Primers
Gene
Crbn
Akt1
Myc
Hif1α
Gata1
Notch1
Tek
Mpl
Vcam1
Cxcr4

TaqMan RefSeq
Mm01182416_m1
Mm01331626_m1
Mm00487804_m1
Mm00468869_m1
Mm01352636_m1
Mm00627185_m1
Mm00443243_m1
Mm00440310_m1
Mm01320970_m1
Mm01996749_s1
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Statistical Analyses
Statistical analyses were conducted using GraphPad Prism Software GraphPad
Software, Inc, La Jolla, CA). Differences between groups were compared using the
unpaired two-tailed multiple Student’s t-test corrected for multiple comparisons using
Holm-Sidak method. Equal variance is assumed between groups. One-way ANOVA
followed by Dunnett’s multiple comparison was performed when comparing multiple
groups. Survival statistics were measured using Mantel-Cox Log-rank test. Statistical
significance was established at **** P <0.0001, *** P<0.001, ** P <0.01, * P<0.05. All data
represented as mean with standard deviation bars representing ± standard deviation. The
number of animals used for biological replicates is listed in figure legends. Technical
replicate experiments (primarily qRT-PCR analysis) are representative of 1-2
independent experiments and contain 3-5 replicates. Group sizes were based on prior
experience with similar studies.
Table 12. Flow cytometry instrument settings
Laser
Wavelength

Power

(nm)

(nm)

488

50

405

100

Detector

Type

DPSS

DPSS

Optical Filters
Fluorochrome

Spectral

Long Pass

Band Pass

Range (nm)

(nm)

(nm)

685-735

685

710/50

PerCPCy5.5

505-525

505

515/20

FITC, BB515

483-493

--

488/10

SSC

755-810

755

780/60

BV785

685-735

670

710/50

BV711

650-670

630

660/20

BV650
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Table 12 (cont.)
Laser
Wavelength
(nm)

640

532

355

Power
(nm)

100

150

20

Detector

Type

DPSS

DPSS

DPSS

Optical Filters
Fluorochrome

Spectral

Long Pass

Band Pass

Range (nm)

(nm)

(nm)

600-620

590

610/20

BV605

570-607*

570

585/42

BV570

505-525

505

515/20

BV510

425-475

--

450/50

BV421

750-810

740

780/60

APC-H7/Cy7

685-735

685

710/50

AF700

663-677

--

670/14

AF647, APC

760-800

740

780/40

PE-Cy7

690-735*

690

710/50

PE-Cy5.5

640-680

640

660/40

PE-Cy5

600-620

595

610/20

PE-CF594

562-588

--

575/26

PE

790-850

770

820/60

BUV805

500-530

450

515/30

BUV496

365-393

--

379/28

BUV395

Instrument Configuration. This panel was developed and optimized for use on BDLSRII flow
cytometry instrument with the listed optical configuration.
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Table 13. Flow cytometry antibodies and panel design
Antibody

Specificity

Fluorochrome

Clone

Staining Conditions

Vendor

Catalog

Vol/Test

Number

(µL)

Vol

T

t
(min)

Step

(µL)

(C)

1

100

4

60

EC

1

100

4

60

EC

Mature Populations
CD45

PE/CF594

30-F11

BV711
CD3

BD

562420

BL

100349

145-2C11
or FITC

BD

553061

RA3-6B2

BL

103236

1

100

4

60

EC

B220

PerCP/Cy5.5

CD41

BV605

MWReg30

BL

133921

1

100

4

60

EC

F4/80

BUV395

T45-2342

BD

565614

1

100

4

60

EC

CD11b

APC

M1/70

BL

101212

1

100

4

60

EC

Ter119

BV510

TER-119

BL

116237

1

100

4

60

EC

CD71

PE/Cy7

RI7217

BL

113812

1

100

4

60

EC

TF

D3571

1

100

4

60

EC

BL

100304

1

100

4

60

EC

1

100

4

60

EC

DAPI
Lineage Cocktail
CD3

Biotin

145-2C11

CD4

Biotin

RM4-5

eBio

CD8

Biotin

53-6.7

BL

100704

1

100

4

60

EC

CD11b

Biotin

M1/70

BD

553309

1

100

4

60

EC

CD19

Biotin

6D5

BL

115504

1

100

4

60

EC

CD127

Biotin

B12-1

BD

555288

1

100

4

60

EC

13-0042-8
5
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Antibody

Specificity

Fluorochrome

Clone

Staining Conditions

Vendor

Catalog

Vol/Test

Number

(µL)

Vol

T

(µL)

(C)

t
(min)

Step

B220

Biotin

RA3-6B2

BL

103204

1

100

4

60

EC

Gr-1

Biotin

RB6-8C5

BD

553125

1

100

4

60

EC

Ter119

Biotin

TER-119

BL

116204

1

100

4

60

EC

BD

562420

100

4

60

EC

BL

405208

1

100

4

60

EC

Stem and Progenitor Populations
CD45

PE/CF594

Streptavidin

APC-Cy7

c-Kit

30-F11

APC

2B8

BL

105812

1

100

4

60

EC

Sca-1

PE-Cy7

D7

BL

108114

1

100

4

60

EC

CD34

PE

RAM34

551387

4

100

4

60

EC

CD135

BV421

A2F10

BL

135314

1

100

4

60

EC

CD150

PerCP/Cy5.5

BL

115922

1

100

4

60

EC

CD 48

BV 605

BL

103441

1

100

4

60

EC

1

100

4

60

EC

1

100

4

60

EC

1

100

4

60

EC

TC15-12F
12.2
HM48-1

BD

Ghost Dye
BV510

Tonbo

Viability Dye

TB-13-087
0-T500

Congenic Markers

CD45.1

CD45.2

PE
or
BV711

A20

APC/Cy7

104

Tonbo
BL

Tonbo

TB-50-045
3-U100
110739
TB-25-045
4-U100
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Commercial reagents used in the final panel (Abbreviations: BL, BioLegend; BD, BectonDickinson; eBio, Affymetrix eBioscience; Tonbo, Tonbo Biosciences; TF, Thermo Fischer
Scientific; EC, extracellular staining.
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CHAPTER FOUR
SUMMARY, FUTURE PERCEPTIVES AND CLINICAL IMPLICATIONS
The successful use of IMiD®s in hematological cancers, as well as the
development of PROTACs has brought CRBN to the forefront of various fields, including
oncology and medicinal chemistry. Differences in IMiD® effects on mouse and human
cells have been reported, suggesting differential regulation of CRBN by IMiD®s[15, 100].
In these studies (Chapter 2), we have determined that the non-conserved Ile391 in the
thalidomide binding domain of mouse CRBN thalidomide-binding domain (TBD) does not
alter its binding affinity with immunomodulatory drugs and that mouse CRBN can trigger
CRBN-dependent degradation of BRD4, confirming that the CRBN/DDB1/Cul4A/Rbx1
complex is indeed functional in mouse cells. However, our work also established a critical
difference between substrate recruitment of mouse and human CRBN, highlighting the
impact this difference will have on the development and testing of novel IMID®s and
PROTACs. Because mouse CRBN is incapable of degrading the IMiD®-associated (in
human cells) neo-substrates IKAROS, AIOLOS, and CK1α, and potentially other
unidentified targets that contain β-hairpin-loop tertiary structure that the form van der
Waal interactions with V388, careful consideration of appropriate preclinical models must
be taken to accurately assess potential/unexpected drug effects in humans.
The development of homo-PROTACs that degrade cereblon has provided a useful
tool to study the endogenous function of cereblon across different cell types and
diseases[57]. Preliminary studies conducted in our lab using a novel cereblon degrader
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demonstrated a potential to expand human T cells in vitro, to improve effector function in
tumor-infiltrating lymphocyte (TIL) therapy and to sensitize tumor cells to chemotherapy.
Additionally, our cereblon degrader was functional in mouse T cells in vitro and showed
promising pharmacodynamics, pharmacokinetics properties and target engagement
when orally administered to mice.
Furthermore, homo-PROTAC cereblon degraders will serves as valuable tools in
the exploration of the effects of acute versus chronic deletion of CRBN in HSC and in the
identification of key endogenous players (e.g. substrates) in CRBN-mediated regulation
of HSC cell fate. For example, oral administration of a CRBN degrader over short or
extended periods followed by lineage output monitoring via flow cytometric analysis of
peripheral blood, bone marrow and spleen will provide additional evidence that indeed
CRBN ablation increases differentiation capacity and thereafter a subsequent loss in
HSPCs. Additionally, the use of a cereblon degrader may distinguish between speciesdependent IMiD®-mediated or endogenous protein regulation, which could provide
critical information in preclinical drug design. Using these new agents, it may be possible
to appreciate the physiological roles for CRBN in protein regulation since it is evident that
it plays a fundamental role in both IMiD®-mediated and endogenous intracellular protein
regulation.
Our work has also highlighted a novel therapeutic vulnerability due to CRBN’s
regulation of HSC cell fate in hematological malignant cells (Chapter 3). Chemical
depletion of cereblon could target quiescent and drug resistant minimal residual disease
(MRD) and leukemia initiating cells (LIC) by suppressing quiescence and stimulating
susceptibility to chemotherapy. Furthermore, since we observe a decrease in mRNA
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expression of Cxcr4 ,Vcam-1 and Tek (gene encodes Tie2) in stem cells that lack CRBN,
CRBN ablation has the potential to target cell adhesion-mediated drug resistance
facilitated by CXCR4/CXCL12 , VCAM-1/VLA-4 and TIE2/ANG-1 interactions[189]. Our
studies presented here as well as in previous works[58, 142], highlight a potential role
for CRBN-mediated regulation of metabolism. Future assessment of CRBN’s role in
regulating metabolic activity of hematopoietic and immune cells may highlight CRBN as
a potential novel therapeutic target for metabolic disorders such as cutaneous lupus
erythematosus (CLE), rheumatoid arthritis, multiple sclerosis and diabetes. Through
modulation of CRBN expression/function it may be possible to inhibit aberrantly regulated
metabolic pathways in cells that rely on an overactive metabolism for survival. Indeed
non-malignant diseases such as cutaneous lupus, a condition whereby immune cells
attack the body’s own tissues as due to impaired immunosurveillance, are now being
effectively treated with IMiD®s [190-192]. This clinical activity has been difficult to
comprehend given the potentiating effects of IMiD®s on T cells, a cell population that is
hyperactivated in these autoimmune diseases.

In a trial of 59 patients receiving

allogeneic stem cell transplantation, the potentiation of T cells was evident from an
increased severity of GVHD in a thalidomide-treated cohort compared to a group
receiving placebo [193]. However, thalidomide was developed in 1953 where it was
widely released to the public based on rodent models that led to the belief that the drug
is nontoxic to humans. After the teratogenic effects were discovered by a German
pediatrician and geneticist linking it to the induction of congenital abnormalities when used
in pregnancy [194, 195], the drug gained traction for profound clinical activity in a patient
with erythema nodosum leprosum (ENL)[196]. As a severe inflammatory condition
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associated with leprosy, this clinical activity led to the subsequent research of thalidomide
in other inflammatory conditions including sarcoidosis, cutaneous lupus, inflammatory
bowel diseases, ankylosing spondylitis and rheumatioid arthritis.

Mechanistically,

responses of IMiD®s in inflammatory conditions has been linked to the suppression of
TNFα mRNA and NFκB DNA binding [197] as well as IL-6 and IL-12 [198]. However, our
research demonstrating the direct functions of CRBN on hematopoiesis generates
rationale for development of a pure agonist – to degrade neo-substrates, and pure
antagonist – to suppress CRBN.

While these two mechanisms are occurring

simultaneously in the current IMiD® compounds, separation of the activity may induce
distinct clinical outcomes.
Finally, the continued investigation of regulators of HSC cell fate will enhance our
understanding of stem cell biology and could positively impact the use of hematopoietic
stem cell transplantation (HSCT) and other HSC-based clinical applications. HSC
expansion ex vivo and in vivo is dependent on the balance among various cell fates
including quiescence, self-renewal, differentiation, apoptosis, and migration. Previous
attempts to obtain higher numbers of transplantable HSC, in both allogeneic and
autologous HSCT, to achieve rapid and sustainable engraftment have had limited
success[199-202]. Since CRBN deficient HSC show enhanced long-term self-renewal
capacity in non-competitive transplantation, a “block” in HSC aging phenotypes and
increased differentiation potential, the modulation of CRBN expression could provide a
mechanism to enhance the persistence of HSCs following transplantation. Moreover, the
increased proliferative state of Crbn-/- HSC may enhance targeted genome editing
techniques in HSCs and/or improve the ability to expand such manipulated HSCs ex vivo.
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In conclusion, our work has highlighted important aspects of the biochemical
properties and cell biological functions CRBN. Our studies strongly support the need for
continuing the elucidation of these biochemical properties and cell biological functions in
the context of both the normal function of CRBN, as well as its altered activity in response
to IMiD® therapies. Our studies presented here along with such future studies will provide
important contributions to the preclinical development of PROTAC compounds.
Ultimately, understanding the integrated constituents required for HSC cell fate decisions
will have a profound impact on HSC-based therapeutic approaches, and for additional
discoveries of regulatory components of HSC fate.
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APPENDIX A
INSTITUTION REVIEW BOARD

3/12/2014
Dana Rollison, Ph.D.
H Lee Moffitt Cancer Center
12902 Magnolia Drive
Tampa , FL 33612
RE: Expedited Approval for Initial Review
IRB#: Pro00016372
Title: Prospective Study of Cutaneous Viral Infections and Non-Melanoma Skin Cancer MCC# 17755
Study Approval Period: 3/10/2014 to 3/10/2015
Dear Dr. Rollison:
On 3/10/2014, the Institutional Review Board (IRB) reviewed and APPROVED the above
application and all documents outlined below.
Approved Item(s):
Protocol Document(s):
Protocol (version 1, 01/31/2014)
Consent/Assent Document(s)*:
Informed Consent (version 1, 02/26/2014) - clean.pdf
*Please use only the official IRB stamped informed consent/assent document(s) found under the
"Attachments" tab. Please note, these consent/assent document(s) are only valid during the
approval period indicated at the top of the form(s).
It was the determination of the IRB that your study qualified for expedited review which
includes activities that (1) present no more than minimal risk to human subjects, and (2) involve
only procedures listed in one or more of the categories outlined below. The IRB may review
research through the expedited review procedure authorized by 45CFR46.110 and 21 CFR
56.110. The research proposed in this study is categorized under the following expedited review
category:
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(2) Collection of blood samples by finger stick, heel stick, ear stick, or venipuncture as follows:
(a) from healthy, nonpregnant adults who weigh at least 110 pounds. For these subjects, the
amounts drawn may not exceed 550 ml in an 8 week period and collection may not occur more
frequently than 2 times per week; or (b) from other adults and children, considering the age,
weight, and health of the subjects, the collection procedure, the amount of blood to be collected,
and the frequency with which it will be collected. For these subjects, the amount drawn may not
exceed the lesser of 50 ml or 3 ml per kg in an 8 week period and collection may not occur more
frequently than 2 times per week.
(3) Prospective collection of biological specimens for research purposes by noninvasive means.
(7) Research on individual or group characteristics or behavior (including, but not limited to,
research on perception, cognition, motivation, identity, language, communication, cultural
beliefs or practices, and social behavior) or research employing survey, interview, oral history,
focus group, program evaluation, human factors evaluation, or quality assurance methodologies.
As the principal investigator of this study, it is your responsibility to conduct this study in
accordance with IRB policies and procedures and as approved by the IRB. Any changes to the
approved research must be submitted to the IRB for review and approval by an amendment.
We appreciate your dedication to the ethical conduct of human subject research at the University
of South Florida and your continued commitment to human research protections. If you have
any questions regarding this matter, please call 813-974-5638.
Sincerely,

E. Verena Jorgensen, M.D., Chairperson
USF Institutional Review Board
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